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ABSTRACT
Both metabolic and cognitive dysfunction can originate from fetal reprogramming precipitating
from adverse conditions experienced in utero. Of note is the western diet (WD), which is
associated with maternal energy imbalances that may hinder fetal development through altered
placental function. Brain-derived neurotrophic factor (BDNF), a growth factor that supports the
placenta and developing brain, is responsive to such energy imbalances. This study sought to
investigate the impact of lifelong maternal WD consumption on fetoplacental development,
focusing on relations between placental changes, and fetal growth and neurodevelopment in a
guinea pig model. Maternal WD consumption resulting in a lean metabolically unhealthy
maternal phenotype was associated with lean fetal hepatic steatosis. Placentae of these fetuses
were large yet inefficient and showed reduced BDNF expression. Similar reductions in BDNF
were noted in fetal brains, coinciding with decreased cell density. Such cellular changes may
convey long-term cognitive deficits, although their consequences remain unknown.
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LAY SUMMARY
Over the last century, rates of metabolic disease and mental illness have risen. While once
thought to possess distinct pathologies, metabolic and cognitive dysfunction show commonalities
in their etiology; both may originate from adversity experienced in utero through the process of
fetal reprogramming. Adverse intrauterine conditions can lead to changes in the development of
the placenta, a critical organ with diverse function that exists to support the developing fetus.
Abnormal placental function translates to altered fetal development, predisposing the child to
later disease. As such, optimizing the maternal environment to foster healthy placental
development is critical to minimizing the child’s risk of disease. While obesity has been
identified as a risk factor to fetal development, it is difficult to distinguish between detriments
caused by obesity, versus the lifestyle factors which precede its development. Of note is the
Western Diet (WD); rich in saturated fat and added sugar, the WD is associated with the onset of
metabolic and neurological dysfunction. Despite its prevalence, little is understood about the
risks associated with habitual WD consumption before and during pregnancy. This study sought
to investigate how lifelong maternal WD consumption would impact the development of the
placenta and fetus, focusing on fetal growth and brain development in a guinea pig model. Both
maternal and fetal populations exposed to the WD developed fatty livers yet maintained lean
body compositions. The placentae of these animals were oversized, inefficient, and showed
significant tissue damage. In addition, these placentae showed lower levels of a growth factor
essential for placental and fetal brain development. Similar reductions in the growth factor were
noted in the fetal brain of those born to WD-fed mothers, which coincided with reduced brain
cell density. Taken together, habitual WD consumption before and during pregnancy may
convey both metabolic and neurological complications to the fetus, possibly through alterations
in growth factor production. The significance of these findings is magnified by their occurrence
in a “lean” model, which emphasizes that evaluating lifestyle factors such as dietary patterns in
parallel with markers of maternal metabolic health is potentially more pertinent to assessing
pregnancy risk than BMI alone.
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CHAPTER 1: LITERATURE SEARCH
1.1 Western Diet and Health Outcomes
1.1.1 Western Diet
A dietary pattern encompasses the quantity, variety, and combination of foods and
beverages habitually consumed by an individual. Numerous dietary patterns exist around the
world established based on cultural differences, socioeconomic status, resource availability, and
ethical practices. These diets can vary greatly in their nutritional value and their impact on
overall health. One such dietary pattern is the Western Diet (WD), a nutritionally poor,
calorically dense diet that is characterized by high levels of saturated fats and added simple
sugars. Following the Neolithic and Industrial revolutions, human nutrition shifted towards the
consumption of refined foods with added sugars and domesticated meats with higher fat content,
giving advent to the WD1. While this dietary pattern originated in North America, the increased
affordability and accessibility of processed and pre-packaged foods, along with global economic
growth, globalization, and urbanization, have led to its global adoption2. Unsurprisingly, the
growing popularity of the WD has been paralleled by rising rates of obesity and metabolic
disease1.
Macronutrients (proteins, lipids, and carbohydrates) are required for the body to function,
but increasing evidence suggests that not all sources of macronutrients are created equal.
Saturated fatty acids (SFAs) such as lauric, myristic, palmitic, and stearic acids, are typically
found in dairy products and fatty meats. SFAs are more calorically dense and are considered proinflammatory3. When consumed in excess (>10% of caloric intake), they are associated with a
greater risk of atherosclerosis as they promote the production of low-density lipoprotein (LDL)
cholesterol3,4. This contrasts monounsaturated fatty acids (MUFAs) like oleic acid and polyunsaturated fatty acids (PUFAs) such as linoleic and α-linoleic acids, which have been found to
lower one’s risk of heart disease by the opposite effect3. Within the PUFA family, omega-3 fatty
acids (α-linoleic, eicosapentaenoic acid, and docosahexaenoic acid) have been highlighted for
their benefits to brain function, heart health, glucose tolerance, and skeletal muscle metabolism
due to their anti-inflammatory and antioxidant properties5. Looking to the WD, which features an
abundance of SFA with minimal MUFAs and PUFAs, it is likely that the relative ratios of these
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fatty acids contribute to the development of many of the metabolic dysfunctions associated with
the diet’s habitual consumption3.
The WD typically contains a low proportion of dietary fibre and few fruits and
vegetables, which although a source of natural sugar also supply micronutrients and
antioxidants6. Instead, carbohydrates in the WD are largely sourced from added simple sugars
like high-fructose corn syrup, offering no additional nutritional benefit7. As with SFA, refined
sugars when consumed in excess can lead to increased risk of metabolic conditions, including
heart disease, non-alcoholic fatty liver disease (NAFLD), and type-2 diabetes, as well as
cognitive disorders like dementia and depression7–10. Conversely, a diet high in fibre maintains
colorectal health, promotes a healthy gut microbiome, lowers LDL cholesterol, and regulates
blood sugar levels11.
Considering the diet as a whole, the WD is associated with increased production of
reactive oxygen species (ROS) and oxidative stress, the development of hyperinsulinemia and
insulin resistance, low-grade inflammation, and abnormal activation of the sympathetic nervous
system1. Increasing evidence suggests that the detrimental effects of the WD are related to its
impact on the gut microbiome12. The WD promotes dysbiosis, a shift in the bacterial populations
cultivating the colon such that there are greater proportions of “bad bacteria” (Ex.
Enterobacteriaceae) relative to “good bacteria” (Ex. Lactobacillus)12. Good bacteria are
classified as such due to their vital role in maintaining the integrity of the colon and in releasing
anti-inflammatory cytokines12. Conversely, bad bacteria increase the permeability of the colon,
promoting the passage of endotoxins into systemic circulation, and increasing the release of proinflammatory cytokines12. Through these changes, the habitual consumption of the WD promotes
a multitude of metabolic diseases and is increasingly being considered as a proponent of
disruptions across multiple organ systems, including the central nervous system1.
1.1.2 Obesity and Metabolic Health
Obesity is a progressive chronic disease that is characterized by abnormal or excessive fat
accumulation (BMI ≥30 kg/m²). In 2016, The World Health Organization estimated that globally
there were 2 billion adults (39%) who were overweight and 650 million (13%) who were
classified as obese. If current trends continue, they predict that rates of obesity will nearly double
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by 2025. These statistics are concerning because as a multi-system disease, obesity has a host of
associated co-morbidities, including type-2 diabetes, dyslipidemia, cardiovascular disease, and
non-alcoholic fatty liver disease (NAFLD)13.
Generally speaking, obesity arises due to a chronic surplus of energy intake relative to
energy expenditure, which ultimately promotes the storage of triglycerides as adipose tissue1.
Beyond this simplified explanation is a complex energy balance equation that includes genetic
and epigenetic factors, endocrine signalling, dietary patterns, lifestyle, and physical activity1,13,14.
While obesity is a growing epidemic that can have severe complications, the obese
classification alone does not preclude health. Obesity is commonly classified based on body
mass index (BMI), which is calculated solely from weight and height. As such, BMI offers little
information about an individual’s insulin sensitivity, blood pressure, blood lipid profile, or
systemic inflammation, which are among the factors that determine metabolic health15. It follows
that the obese classification captures individuals of varying metabolic health, including those
who carry no additional risk for metabolic disease termed the “metabolically healthy obese”15–18.
Conversely, metabolic dysfunction may arise in the absence of obesity as a “lean metabolically
unhealthy” phenotype15–18. While often out shadowed by discussions around obesity, this lean
metabolic dysfunction conveys similar detriment to long-term health and describes a significant
proportion of individuals, affecting approximately 20% of the population (estimated from the
US)18. As a relatively novel area of study, the factors that favour the development of one
metabolically unhealthy phenotype over another are not yet clear, although it is currently largely
attributed to genetic factors15.
Amongst both populations, NAFLD is a prominent feature of metabolic dysfunction and
poses its own risks to long-term health. NAFLD is a broad term used to describe a spectrum of
progressive conditions that results from fat deposition in the liver unrelated to alcohol or viral
causes19,20. This spectrum begins with triglyceride accumulation in the absence of inflammation;
but over time, the disease progresses into non-alcoholic steatohepatitis (NASH), which is
characterized by hepatic inflammation19. With this inflammation comes increasing fibrosis that
eventually culminates in cirrhosis and liver failure19.
While obesity itself is a risk factor of this disease, NAFLD is increasingly being
identified in individuals with a lean phenotype. Globally, around 40% of those with the disease
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are considered non-obese, and almost 20% were deemed lean21. Unfortunately, a lean phenotype
does not preclude an individual from liver damage as multiple studies have indicated that those
with lean NAFLD are at higher risk of developing severe liver disease compared to their obese
counterparts22,23. Outside of disease progression, lean NAFLD also communicates greater risk
than metabolically healthy obesity for the development of type-2 diabetes24. This once again
highlights the importance of adopting a holistic understanding of metabolic health that
adequately identifies the risks incurred by lean metabolically unhealthy individuals.
Multiple risk factors for the development and progression of this disease have been
identified; however, the exact etiology is not fully understood20. It is suspected that
hyperinsulinemia and insulin resistance play a key role in its pathophysiology by increasing the
release of free fatty acids from peripheral adipose stores and decreasing free fatty acid oxidation
in skeletal muscle and liver19,25. The result is an imbalance in the supply and utilization of free
fatty acids that not only promotes its accumulation in hepatocytes but also leads to the
production of ROS and inflammation through mitochondria dysfunction19.
As a major proponent of insulin resistance, WD consumption is strongly associated with
NAFLD19. High-fructose corn syrup, for example, is a simple sugar abundantly found in the WD
that is considered more lipogenic than other complex sugars and has been found to induce
hepatic inflammation26,27. Prior to the onset of insulin resistance, the high glycemic index of the
WD leads to rapid increases in insulin and postprandial blood glucose, which further promotes
liver lipogenesis25. Moreover, hypertriglyceridemia is correlated with the development and
severity of NAFLD independent of obesity and other metabolic conditions, emphasizing the
important role of diet in disease progression28,29.
In sum, metabolic dysfunction in all its forms represents a severe public health crisis.
While the exact phenotype, lean or obese, may be largely dependent on uncontrollable factors
like genetics, lifestyle factors such as habitual WD consumption still perpetuate the development
of metabolic dysfunction regardless of body size.
1.1.3 Western Diet and the Brain
Obesity and metabolic disorders have long been considered independent of cognitive
dysfunctions as they implicate different regions of the brain. The hypothalamus is well
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established as a regulator of energy balance30,31. It follows that experimental manipulations of the
hypothalamus in animal models have profound effects on eating behaviours and body mass, and
in humans, energy imbalances have been associated with alterations in neurohormone signalling
pathways within the hypothalamus31. On the other hand, cognitive dysfunction and mood
disorders are thought to arise from alteration at the hippocampus, a brain region primarily
responsible for learning and memory32–34.
Increasing evidence posits that the WD is a common etiology of both metabolic and
cognitive impairments and that the two may be intrinsically linked. The hippocampus is
particularly sensitive to a variety of stressors including metabolic perturbations and energy
imbalances34,35. In addition to metabolic diseases, the consumption of the WD has been strongly
correlated with increased incidence of Alzheimer’s disease and milder forms of cognitive
impairment that involve hippocampal structures36–39. These impairments may be the consequence
of WD-induced changes in glucoregulation, neurotrophin levels, neuroinflammation, and bloodbrain barrier integrity that directly or indirectly induce hippocampal dysfunction40,41.
High levels of saturated fats and refined sugars contribute to the development of insulin
resistance and glucose intolerance42. Insulin and its receptor are abundantly expressed in the
hippocampus and at optimal doses, insulin has been shown to enhance memory in rodents and
humans43,44. Consequently, poor glycemic control and subsequent insulin resistance, independent
of BMI, hypertension, and dyslipidemia, were previously linked to memory impairments and
hippocampal atrophy in humans45. Healthy brain function and ongoing processes that mediate
memory and learning at the hippocampus are similarly supported by other hormones and growth
factors, the expression of which may be altered by energy-status46,47. Brain-derived neurotrophic
factor (BDNF), for example, has been described as a mediator of WD-induced neurological
changes because its expression in both human and animal models is largely impacted by changes
in energy balance and more specifically, is reduced by WD consumption47,48. The effects of the
WD on neurotrophic factor expression may also involve inflammation. SFA specifically are
considered pro-inflammatory, and when consumed in high proportions, as is characteristic of the
WD, have been associated with chronic low-grade inflammation3. Neurotrophic factors like
BDNF help to mediate anti-inflammatory responses to acute inflammation that facilitate tissue
remodelling following brain injury; however, chronic inflammation has been found to
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downregulate neurotrophin expression, thus perpetuating continuous inflammation and
hampering tissue repair49,50. In addition, disrupting the integrity of structures such as the bloodbrain barrier (BBB) may also perpetuate neuroinflammation and cognitive impairment51,52.
Specifically, the WD was found to reduce the expression of tight junction proteins, which would
normally restrict the permeability of the BBB, in a rodent model40. A “leaky” BBB fails to
prevent toxins and pathogens from entering the CNS, which may then disrupt the neural
environment leading to poor cognitive outcomes40.
In addition to memory and learning deficits, the hippocampus is also postulated to be
involved in regulating eating behaviours, as experimentally induced hippocampal lesions result
in obesity and hyperphagia53,54. The exact mechanism behind this effect has not been elucidated;
however, it has been postulated that impairing hippocampal-dependent memory may interfere
with the ability of satiety cues to suppress the memory of positive reinforcement achieved
through eating, leading to poor appetite control and increased energy consumption41.
Taken together, the WD and subsequent metabolic dysfunction are likely detrimental to
adult brain health, disrupting sensitive structures like the hippocampus. These hippocampal
disruptions likely result in both cognitive impairment and further metabolic dysfunction. Given
the detriment noted in the adult brain, these findings also beg the question of whether maternal
WD consumption and metabolic dysfunction may evoke similar detriments to fetal development.

1.2 Developmental Programming of Neurodevelopment
1.2.1 Fetal Programming
During critical periods of development, adverse events in the maternal environment can
have a significant impact on the short and long-term health outcomes of the fetus55,56.
Unfavourable conditions during pregnancy lead to developmental adaptations in the fetus that
alter its structure, physiology, and metabolism, thus ‘programming’ susceptibility to later
disease57. This is the foundation of what is now referred to as ‘The Developmental Origins of
Health and Disease’ (DOHaD) hypothesis.
This theory came to fruition through multiple epidemiological observations, the first
being from Dr. Anders Forsdahl in 1977 who reported a correlation between early-life poverty
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and adulthood cardiovascular disease58. He speculated that nutritional deficits incurred during
early childhood may result in permanent damage that predisposes the development of
cardiovascular disease in adulthood58. These observations were then furthered in conjunction
with epidemiologist Dr. David Barker and his colleagues who extended the findings to a fetal
population, suggesting poor nutrient availability in utero leads to fetal adaptations that program
the development of adult-onset non-communicable disease (cardiovascular disease, obesity,
metabolic disease, stroke, and type-2 diabetes)55,56,59,60. Since its advent, this hypothesis has
found application in explaining fetal health outcomes under various adverse intrauterine
conditions including malnutrition, overnutrition, infection, chemical exposure, hypoxia, and
hormonal perturbations57,61.
Research has tried to elucidate the underlying mechanism behind these programmatic
changes. While there is no single mechanism that will explain the multitude of observed
phenomena, three primary mechanisms have been identified, although there are likely more that
exist.
First is through permanent structural changes to fetal tissues61. Suboptimal delivery, both
elevations and reductions, of nutrients, hormones, or substrates needed for appropriate
development may permanently alter the structure of the fetal tissues61–65. This effect is
particularly prominent in the brain, where a reduction in neurotrophin delivery can reduce cell
proliferation and alter neurogenic processes, thus altering the structural connectivity of the brain
as has been shown in multiple animal models47,61,64,66.
Second is through the epigenetic regulation of multiple genes61. Epigenetics refers to
DNA modifications that do not alter the DNA sequence itself but instead alter its expression67.
These modifications include DNA methylation/acetylation, histone acetylation and non-coding
RNA67. They contribute to cellular memory, eliciting change that persists even following
multiple rounds of cell division67. When transcription factors are the target of this regulation,
epigenetic marks on a single gene can influence an entire network of genes. For example,
nutritional pregnancy challenges have been found to alter methylation patterns in various genes
involved in carbohydrate and lipid metabolism, eliciting changes that may only become apparent
when the individual is exposed to post-natal dietary stress (ex over or under nutrition) 67–69.
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Finally, adverse events can alter the expression of proteins related to cellular senescence
and can induce oxidative stress, both of which accelerate cellular ageing61,70. Consequently, this
increases the risk of developing conditions that are associated with ageing, which includes many
metabolic and neurodegenerative diseases61. Pre-natal adverse events can induce oxidative stress
either by increasing fetal hypoxia, reducing anti-oxidant defence mechanisms, or altering
mitochondrial function57,71. The latter two mechanisms are common features of maternal obesity
and WD consumption, both of which increase ROS production57,72. Elevated levels of ROS
damage lipid membranes, proteins, and DNA, thus accelerating the rate of tissue ageing and
elevating the risk of developing age-related pathologies57,61.
Collectively these mechanisms help to explain some of the long-term health outcomes
noted under various forms of maternal stress. While the DOHaD hypothesis was initially used to
explain the prevalence of metabolic health conditions, research has found evidence of its
importance in programming fetal brain development as well73–75.
1.2.2 Placental Development
Placental development begins following the implantation of the blastocyst, the outer layer
of which is made up of trophoblast cells that will eventually derive the placental structures76.
Trophoblasts differentiate into an outer layer of syncytiotrophoblasts and an inner layer of
cytotrophoblasts76. The syncytiotrophoblasts are highly invasive cells that erode maternal tissues
and blood vessels, filling the lacunae—empty spaces within the syncytiotrophoblast layer—with
maternal blood76. Cytotrophoblasts are proliferative cells that continuously grow to form
projections that extend into the surrounding syncytiotrophoblast cells76. With further
development, extra-embryonic mesoderm and embryonic blood vessels form within these
projections forming what is termed the tertiary chorionic villi76. As pregnancy advances, these
villi undergo expansive branching, forming tree-like structures within the intervillous space that
contain a network of fetal blood vessels and are optimized for gas and nutrient exchange76,77
In addition to these “floating” villi, anchoring villi extend to the basal plate (maternal
side of the placenta) and provide support to the placental structure77. From the distal ends of
these villi, cytotrophoblasts differentiate into extravillous trophoblasts (EVT), which migrate into
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the maternal decidua and invade the myometrium where they remodel uteroplacental arteries77.
This process ensures adequate blood flow and nutrients are accessible to the developing fetus77.
By the end of placental development, a network of developed branching villi protrudes
into the intervillous space where they are bathed in nutrient-rich maternal blood76.
Syncytiotrophoblasts, which cover the surface of these placental villi are in direct contact with
maternal blood and are critical for mediating many of the placenta’s functions, including
hormone production and nutrient/gas exchange78.
Across various animal species, there are differences in the structure of the placenta, one
of which being in the cellular layers making up the placental barrier. The placentae of common
rodent models like the rat or mouse possess a haemotrichorial barrier with three layers of
trophoblast cells separating the maternal blood space from the fetal capillaries79. This structure
contrast that of the human placenta, which is haemomonochorial with only a single layer of
syncytiotrophoblast cells at the maternal-fetal interface79. The guinea pig model is often used as
a pre-clinical animal model of pregnancy because, unlike other rodents, it too possesses a
haemomonochorial placenta79,80. In addition to their similarities at the exchange interface, both
human and guinea pig trophoblast cells invade deeply into the decidua, contrasting the shallower
invasion noted in other rodent models80. Despite its similarities to the human placenta, some key
differences distinguish the two placentae80. For example, the guinea pig placenta includes a
subplacenta, which is a region of the placenta that connects the placenta to the junctional zone,
analogous to the anchoring villi of the human placenta80. Rather than branching placental villi,
the guinea pig placenta possesses a labyrinth region made up of a mass of syncytiotrophoblast
cells that surround maternal lacunae and fetal capillaries80. This structure supports a
countercurrent exchange system that differs from the concurrent exchange system of the human
placenta80. Regardless of the species, it is these various placental structures and cell types that
mediate exchange and communication between the maternal and fetal environment, making their
formation a critical determinant of healthy fetal development.
1.2.3 Brain Development
Development of the fetal nervous system begins on the 4th week of gestation following
neurulation and continues into early adulthood81. The neurodevelopmental timeline begins with
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the rapid proliferation of neuroprogenitor cells in the ventricular and subventricular regions of
the fetal brain through symmetrical cell division81. Neuroprogenitor cells gradually transition to
asymmetrical division, producing an identical neuroprogenitor cell to replenish the progenitor
pool, as well as an additional cell with a distinct cell fate81. These neuroprogenitor cells, also
referred to as radial glia, give rise to three major cell types: neurons, oligodendrocytes, and
astrocytes. Neuroprogenitors destined to become neurons will give rise to immature neurons,
which migrate out to the developing neocortex where they differentiate into specialized neurons,
creating multiple layers and neural structures that contain functionally distinct cell types81. The
axonal and dendritic processes of positioned neurons begin to develop, forming synapses and
allowing them to integrate into a growing network of cells81. With the development of other
neural cell types, namely oligodendrocytes, the axons become myelinated in specific patterns
that ensure proper conduction across neural circuits81,82.
Oligodendrocytes are a type of macroglial cell, much like astrocytes. The generation of
these cells, referred to as gliogenesis, begins late in the embryonic stage following the start of
neurogenesis and continues, although to a much smaller extent, into adulthood83. Glial cells
make up most of the brain cells and are essential for maintaining the homeostasis of the mature
brain, as well as supporting neurodevelopmental processes like cell migration, myelination, and
synaptogenesis83.
In addition to the macroglia cells, another type of glial cell exists called microglia.
Contrary to neurons and macroglia, these cells do not arise from ectoderm-derived
neuroprogenitor cells; rather, these cells are derived from primitive macrophages of the yolk sac
that begin to populate the developing nervous system early in development alongside the
neurons84. While microglia are primarily known for their immune function, they also mediate
regressive developmental events like neuronal apoptosis and synaptic pruning81,85. Following
expansive cell proliferation and synaptogenesis, the microglia help to eliminate excessive or
dysfunctional cells and synaptic connections, which refines neural circuitry81. Synaptic pruning
is an example of a developmental process that continues well into adulthood, contributing to
what is termed synaptic plasticity, a process that is essential for learning and memory81,83.
A second component contributing to synaptic plasticity is hippocampal neurogenesis.
While most neuroproliferation occurs in utero, in select regions of the brain, specifically the
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hippocampus, the process similarly continues into adulthood81,86,87. The hippocampus is one
component of the limbic-cognitive system, a system involved in learning and memory,
attentional processes, motivational states, and emotions88,89. Hippocampal neurogenesis
specifically, is largely involved in memory formation, learning, and behaviour, and deficits in
this process are thought to underlie the development of cognitive deficits and mood disorders
like depression and schizophrenia87–89.
Progression through this developmental timeline (Fig 1.2.3-1) in utero and beyond is
guided largely by neurotrophic factors and neurotransmitters, alterations of which can alter longterm brain connectivity and function81. Similarly, aberrations in non-pathological regressive
processes can pose significant detriments to the developing brain. As previously mentioned,
microglia are immune cells in the central nervous system that protect the neural tissues from
pathogens and maintain homeostasis81,90. During early development, these cells play an
additional role in refining neuronal circuits by mediating neurogenesis and synaptic pruning81,90.
While a certain level of neuroinflammation is essential for neurodevelopment, aberrant chronic
early-life inflammation may alter the programming of the microglial population such that the
threshold required for reactivation is reduced, predisposing the individual to inflammatory
damage later in life90. Healthy neurodevelopment thus depends on a delicate balance of trophic
signals promoting neurogenesis, and the activation of microglial-mediated inflammatory and
anti-inflammatory pathways that “clean-up” neural circuitry90.
Many of these developmental processes are conserved across species; however, the
timing of these events can differ (Fig 1.2.3-2)91. Animals like the rat or mouse are postnatal brain
developers, meaning that they are born with relatively immature brains that undergo significant
development postnatally91. Unlike most other rodents, guinea pigs give birth to precocial young
and are considered prenatal brain developers91. Their young are born with highly developed
brains comparable to that of a mouse approximately 30 days after birth91. Human
neurodevelopment is somewhere in the middle; while significant brain development does occur
in utero, it begins to slow towards the end of pregnancy, then continuing postnatally91.
Understanding the differences between developmental timelines is essential in interpreting and
translating scientific findings on neurodevelopment across species.
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Figure 1.2.3-1. Timeline of human brain development.

Figure 1.2.3-2. Comparison of brain development timeline between humans, guinea pigs, and
mice. Figure adapted from Workman et al91.
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1.2.4 The Placenta’s Role in Fetal Neurodevelopment
It is impossible to discuss the DOHaD hypothesis without recognizing the importance of
the placenta. The placenta is a transient, but vital organ acting as an interface between mother
and fetus. Aside from the exchange of nutrients and waste, the placenta produces critical
hormones, growth factors, and proteins, acts as an immunological barrier that protects the fetus
from xenobiotic chemicals, and supplies the fetus with molecular substrates needed for processes
like neurodevelopment92,93. These processes depend on the proper structural development of the
placenta.
As a dynamic sensor of the maternal-fetal environment, the placenta can adapt to changes
in the maternal environment to prioritize gas and nutrient transport to the fetus92,93. While these
adaptations ultimately preserve the life of the fetus, they may still disrupt normal placental and
fetal development92,93. Abnormal placental morphology that alters blood flow and nutrient
exchange, as well as alterations in nutrient transporter expression that occur in response to
maternal perturbations, can reduce placental efficiency and have detrimental effects on fetal
development93,94. Brain development is resource-intensive, relying on nutrients supplied from the
placenta to support the rapid expansion of the fetal nervous system95. This makes
neurodevelopment particularly susceptible to aberrations in placental architecture that disrupt
nutrient exchange95.
Just as brain development demands adequate nutrient supply, it also relies on the delivery
of

neurotrophic

factors

and

neurotransmitters

that

direct

progression

through

the

neurodevelopment timeline, some of which may be impacted by imbalances in nutrient
availability93,94. For example, placental-derived BDNF directs cell proliferation, among other
developmental processes in the fetal brain, and its expression is tightly regulated by maternal
energy status96–98. Consequently, disrupting the early supply of this factor may then alter early
brain development, affecting its receptors’ expression and local production in the adult brain,
eliciting future cognitive impairment96,97.
It is postulated that many of these changes in placental function are manifestations of
altered gene expression occurring because of epigenetic changes93,99,100. The exact mechanism
underlying these differences is not fully known. It is suspected that altered energy balance,
inflammation, or ROS, resulting from adverse maternal conditions (obesity, WD, malnutrition,
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stress, infection, hypoxia) may alter epigenetic machinery and consequently the epigenetic
markings of various placental genes99–101. Subsequent alterations in placental function may then
directly or indirectly program neurodevelopmental change92,101.
It is also postulated that many maternal stressors, both infectious and non-infectious,
induce some form of inflammation within the placenta93. Although the underlying mechanisms
remain unknown, it has been shown that maternal inflammation is detrimental to fetal
neurodevelopment as it has been associated with greater risk of neurodevelopmental disorders
like Schizophrenia and Autism spectrum disorder, as well as cognitive impairement102–106. It is
postulated that placental inflammation may modify fetal neurodevelopment by altering placental
function as described above, or by releasing pro-inflammatory cytokines into fetal
circulation93,107. In the fetal brain, inflammatory cytokines are involved in signal transduction
pathways, which may be disrupted by their aberrant expression107. Moreover, these cytokines
program microglial activation, enhancing their future inflammatory response90.
The placenta has a formative role in fetal neurodevelopment. Consequently, alterations in
its morphological development or function lead to significant changes in brain function in later
life. While questions remain around the exact mechanisms behind placental-mediated neural
programming, inflammation and epigenetic changes are likely implicated.
1.2.5 Maternal Overnutrition and Brain Development
It has been well established that maternal undernutrition is associated with alterations in
fetal neurodevelopment that communicate serious risks for long-term cognitive deficit108. On the
other end of the spectrum, studying maternal overnutrition poses greater challenges as obesity
and diet are often inseparable. Many obese models are achieved through an obesogenic diet
regimen and studies investigating the dietary patterns (WD, high fat, or high sugar) themselves
are typically confounded by weight gain or obesity, making it difficult to identify the risks of the
diet independent of maternal obesity109.
Much like the aforementioned trends in obesity and WD consumption, the prevalence of
neurodevelopmental disorders has increased dramatically110. This led researchers to question the
association between maternal metabolic disease and prenatal diet on offspring behaviour. Indeed,
epidemiological studies have found correlations between maternal obesity, metabolic
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dysfunction, and diet and the development of multiple cognitive disorders, namely attention
deficit hyperactivity disorder, autism spectrum disorder, schizophrenia, anxiety, and depressive
disorders111.
In animal models, including both rodents and non-human primates, offspring exposed to
maternal overnutrition have shown additional deficits in learning and memory, as well as
abnormalities in behaviour97,112,113. Animal models are advantageous in that they offer additional
insight into the neurological changes underlying these outcomes. At a molecular level, maternal
overnutrition has been associated with reduced hippocampal neurogenesis and synaptogenesis in
rodent models, processes that greatly contribute to learning and memory97,114. Moreover, one
study found evidence of increased lipid peroxidation in the hippocampus of mice as a result of
maternal obesity (induced by a high-fat diet), which also led to impaired branching of
hippocampal neurons112,114. This is aligned with previous studies which suggest that obesity and
insulin resistance are associated with increased levels of oxidative stress1,109.
Similarly, both metabolic dysfunction and WD consumption lead to ‘metainflammation’,
a form of chronic low-grade inflammation arising from metabolically active tissues like the
adipose, muscle, and liver experiencing metabolic challenges93,115,116. In animal and human
studies, maternal overnutrition was associated with increased expression of placental genes
related to inflammation and oxidative stress and similarly, increased production of inflammatory
cytokines like tumour necrosis factor, interleukin-6, and toll-like receptor-4117,118. Similar
findings have been noted in the brain. Third-trimester fetuses of high-fat-fed macaque mothers
have shown enhanced microglial activation and elevated levels of proinflammatory cytokines119.
Increases in microglial activation have also been noted in the hippocampus of adult rodent
offspring born from high-fat-fed dams and these changes were accompanied by increased
anxiety-like behaviours and deficits in spatial learning113.
Research has just begun to uncover the effects of maternal overnutrition on fetal brain
development. Given the strong correlation between overnutrition and cognitive dysfunction in
the adult brain, as well as the preliminary evidence of its perinatal influence described above, it
is likely that overnutrition experienced during the critical period of intrauterine development
would confer similar detriment.
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1.3 Brain-Derived Neurotrophic Factor (BDNF)
1.3.1 Overview
BDNF is a member of the neurotrophin family, a group of small secreted proteins that
play an important role in directing neurodevelopment in utero and into adulthood48. Aside from
its critical role in the brain, BDNF has multiple functions in peripheral tissues. Both BDNF and
its receptors are expressed in tissues outside of the central nervous system including, but not
limited to, the skeletal muscle, heart, liver, adipose tissue, and the placenta 120–122
Within most tissues BDNF is expressed constitutively; however, in the brain, production
and release of BDNF are activity-dependent; a calcium influx stimulated by membrane
depolarization triggers downstream signalling pathways resulting in the binding of transcription
factors that stimulate BDNF expression123,124. Synthesis begins with a 32kDa precursor called
pro-BDNF, which is then processed intra-or extra-cellularly into the mature 14kDa protein48. The
extracellular cleavage of pro-BDNF is mediated by plasmin and metalloproteinases, while
intracellular cleavage is mediated by furin and prohormone convertase 1 within the trans golgi
network 48. Secreted BDNF and its precursor mediate their effects through receptor binding and
signal transduction.
The two primary receptors with which BDNF binds are the tropomyosin receptor kinase
B (TrkB) and the p75 neurotrophin receptor (p75NTR)46. The TrkB receptor is a high-affinity
receptor from the tyrosine kinase receptor family that is highly selective for mature BDNF46.
Ligand-binding stimulates receptor dimerization and kinase activation, initiating complex
intracellular signalling cascades48. These signalling pathways have previously been discussed in
detail by Sandhya et al125. Among these pathways, MAPK, PLCγ, and PI3K are most often
highlighted as they mediate the primary cell survival and regenerative functions of BDNF-TrkB
signalling48,123. P75NTR is a low-affinity receptor belonging to the tumour necrosis factor
receptor superfamily46. Unlike the TrkB receptor, it shows minimal binding selectivity in that it
binds multiple analogous neurotrophins; however, it does show a higher affinity for
proBDNF46,126.
Understanding the exact molecular functions of BDNF is made complicated by the
opposing actions of mature BDNF and its precursor, which are often stored and secreted together
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with cellular activity126. Contrary to the function of TrkB, p75NTR generally has pro-apoptotic
functions; but when both receptors are co-expressed, p75NTR promotes ligand discrimination
and increases the binding affinity of TrkB46,123. Evidence also suggests that truncated isoforms of
the TrkB receptor exert dominant negative inhibition of p75NRT, thus preventing cell death127.
Thus, while its primary functions are trophic in nature, it is likely the unique expression pattern
of BDNF, its precursor, and its receptors that define signalling in any given tissue126.
In sum, BDNF is an activity-dependent growth factor, expressed within and beyond the
central nervous system. Through complex signalling pathways, it balances cell growth and
survival with programmed cell death making it an essential aspect of fetoplacental development.
1.3.2 The Role of BDNF in Placental Development
BDNF and its corresponding TrkB receptor are both expressed by decidua and
trophoblast cells of the placenta at various stages of pregnancy 122,128,129.
As early as embryonic development, BDNF-TrkB interactions promote embryo growth
and suppress apoptosis through paracrine signalling mechanisms122. Moreover, they promote
trophoblast proliferation and outgrowth of the blastocyst prior to implantation122.
As pregnancy advances post-implantation, BDNF continues to support the growth and
survival of placental cells122,128. BDNF is expressed by both syncytiotrophoblasts and EVT,
while the TrkB receptors are expressed in cytotrophoblasts and EVTs128. TrkB signalling
promotes the differentiation, proliferation, and survival of cytotrophoblasts and EVTs, two
integral cell types involved in establishing placental structure128,130. Consequently, inhibition of
this signalling pathway has been previously associated with decreased human cytotrophoblast
proliferation and differentiation, and suppressed outgrowth of human EVTs128. Moreover, this
inhibition led to reduced cytotrophoblast cell viability, marked by reduced glucose metabolism
and increased apoptosis, underscoring the importance of BDNF in maintaining placental
integrity128.
A major determinant of fetal growth and development is the placenta’s ability to supply
nutrients, an ability that is dependent on placental size, morphology, blood flow, and transporter
availability131. By promoting the growth and development of the placenta, placental BDNF
effectively supports the growth and development of the fetus. This is evidenced by in vivo
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inhibition of BDNF-TrkB signalling, which was associated with reduced placental and fetal
weights in a murine model122. In addition to placental size, BDNF expression is positively
correlated with gestational age. As pregnancy advances, both BDNF and TrkB expression are
increased in animal and human placentae129. It follows that BDNF expression in the placentae
and fetal cord blood is reduced in preterm human pregnancies132,133.
Aside from its role in cell growth and survival, BDNF has been classified as an
angioneurin—a molecule that affects both neural and vascular functions134. Through binding to
TrkB receptors expressed on endothelial cells, BDNF stimulates angiogenesis in the heart,
skeletal muscle, and skin135. In addition, the absence of p75NTR receptor signalling can lead to
defects in vascular systems, including blood vessel dilation and rupture, and blood cell
leakage136. It is postulated that BDNF may also exhibit the same angiogenic effects in the
placenta, promoting angiogenesis and maintaining the health of vasculature in the fetoplacental
unit133,136,137. Preeclampsia is a pregnancy complication with unknown origin; however, its
etiology is thought to involve altered uteroplacental perfusion resulting from abnormal placental
development138. Reductions in placental BDNF expression have been noted in the placentae of
pre-eclamptic mothers, further suggesting the neurotrophin’s role in supporting vascular
development in the placenta137,138.
Stressors in the maternal environment have a notable impact on placental BDNF
expression. Maternal energy status of either extreme decreases placental BDNF expression130,139.
Maternal obesity specifically was associated with reduced expression of both BDNF and its
receptor and disrupted signalling that occurred in a sexually dimorphic manner in the human
placenta139,140.

Moreover, both acute and chronic maternal psychosocial stress have been

associated with reduced BDNF expression in rodent models141.
In addition to supporting overall placental development, placental BDNF also plays a role
in fetal development. In the absence of BDNF, mouse fetuses either failed to reach term or were
non-viable at birth98. The primary sources of BDNF are endogenous fetal synthesis, placental
production, and maternal passage142. Contributions from these sources differ throughout
pregnancy. Early in gestation, the placenta is a major source of BDNF98. As pregnancy advances
the fetus begins to produce its own supply of BDNF and its reliance on placental BDNF
diminishes98. This period aligns with the cerebral development and maturation of the fetus
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occurring in the latter half of gestation132.

Despite the fetus’ ability to synthesize the

neurotrophin, maternally-derived BDNF has been identified in the fetal brains of mice at term
and concentrations of BDNF in these fetal brains show dose-dependent increases in response to
exogenous maternal BDNF administration98. The importance of the maternal BDNF supply is
further supported by the sharp decline in BDNF in fetal blood noted immediately after birth,
reflecting the abrupt removal of its exogenous sources143. Thus, placental BDNF is a major
contributor of fetal BDNF and alterations in its expression or production may prove detrimental
to fetal development and programming.
In summary, BDNF and its primary receptor are expressed across maternal and fetal
compartments of the placenta. Through signalling mechanisms, BDNF promotes the growth and
development of placental tissue and likely its vascular system. Stressors in the external and
maternal environment can have detrimental impacts on placental BDNF expression, contributing
to poor pregnancy outcomes. As a primary source of BDNF for the developing fetus, the impact
of these alterations likely extends to the fetus itself, programming altered developmental
outcomes.
1.3.3 The Role of BDNF in Early Brain Development
BDNF is most well known for its role in the brain, both during in utero development and
into adulthood. Before the fetal brain can produce its own endogenous supply of BDNF, the
neurotrophin is supplied by the mother and placenta98. As pregnancy advances, the fetus
increasingly relies on endogenous BDNF produced by the cells of its expanding central nervous
system, even though maternally-derived BDNF continues to be supplied across the placental
barrier98. Both BDNF and its precursor are stored in the axons and dendrites of neurons and
released in an activity-dependent manner126. Within the brain, expression is highest in the
hippocampus and hypothalamus with moderate expression in the cerebral cortex, thalamus,
amygdala, and cerebellum46,48.
Throughout fetal development, BDNF is involved in nearly all neuronal processes
including neurogenesis, myelination, synaptogenesis, and synaptic refinement46,144. During the
rapid expansion of the nervous system during the first two trimesters, BDNF mediates cortical
neuro- and glial-genesis by promoting cell proliferation, differentiation, and migration46,126. The
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balance between BDNF and its precursor pro-BDNF helps to determine cell fate and regulate
apoptosis following expansive cell proliferation124,145. This form of regulated apoptosis is
essential for controlling the size of neuron and glial cell populations145. While cortical
neurogenesis is typically completed by gestational week 25 in humans, neurogenesis within the
hippocampus continues throughout gestation and after birth into adulthood through a process that
is similarly supported by BDNF146–148. Both hippocampal infusion and peripheral injection of
BDNF have been associated with dramatic stimulation of hippocampal neurogenesis in various
rodent models149–151. This form of continued neurogenesis is one way in which BDNF
contributes to learning, memory, and neuronal plasticity, chief functions of the hippocampus.
Beginning in the latter half of gestation, BDNF promotes myelination and
synaptogenesis, generating a functional neural network124,144. The majority of myelination occurs
by the first two years of life, although it has been reported that myelination processes may persist
into early adulthood82,144. In addition to promoting the proliferation and survival of
oligodendrocytes, the myelin-producing cells of the central nervous system, BDNF promotes the
synthesis of myelin itself144. Consequently, BDNF-heterozygous mouse models have been
associated with reduced myelin basic protein and altered myelination patterns in the
hippocampus that disrupt cognitive function144.
Much like hippocampal neurogenesis, both synaptogenesis and synaptic refinement begin
in utero, but continue throughout adult-life, and are important mediators of synaptic
plasticity152,153. Specifically, BDNF signalling through the TrkB receptor promotes the growth
and branching of dendritic processes, increasing their size, number, and complexity126,153. Much
like its regulation of neuronal apoptosis, the balance between BDNF and pro-BDNF signalling is
thought to control long-term potentiation and long-term depression by strengthening or
eliminating connections in an activity-dependent manor124,153. Malfunctioning or ineffective
connections are thus removed, while new connections are created and strengthened124. These
functions overlap with the functions attributed to regulated microglial activation. Microglia, like
neurons, regulate their own BDNF secretion, through which it is suspected they modulate
synapse refinement and tissue re-modelling154.
Evidently, BDNF is heavily involved in neurodevelopment in utero and beyond. As such,
deficits in BDNF communicate serious cognitive detriments. Complete BDNF knock-out models
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rarely reach adulthood and typically have severe sensory impairment, reflecting the importance
of the neurotophin32,104. The Val66Met single nucleotide polymorphism is a human mutation in
the BDNF gene that causes decreased BDNF trafficking into activity-dependent secretory
pathways resulting in its reduced expression152. Both Val66Met models and experimental BDNF
inhibition or downregulation have been associated with impairments in learning and memory, as
well as increased susceptibility to psychiatric and neurodegenerative disorders, including
schizophrenia, bipolar disorder, major depressive disorder, and Alzheimer’s disease32,33,104,126,152.
Most of these cognitive outcomes are attributed to deficits in the hippocampus, a region
that is chiefly responsible for learning, memory, and behaviour. It is also a brain structure with
one of the highest levels of BDNF expression, making it a natural target of BDNF inhibition46.
The hypothalamus, which regulates multiple metabolic processes, likewise shows high levels of
expression46. Hyperphagic obesity is a common phenotype attributed to the Val66Met mutation
and is common to animal models with suppressed BDNF or TrkB receptor expression30,152.
Within the hypothalamus, BDNF acts as an anorexigenic agent suppressing food intake30,155. The
role of the hippocampus in eating behaviour has also been described. Specifically, impairing
hippocampal-dependent memory is suspected to affect appetite control by interfering with the
cognitive response to satiety signals41. Apart from appetite suppression, other findings suggest
BDNF may have more direct effects on peripheral energy metabolism through unknown central
nervous system functions and through tissues outside of the central nervous system, namely the
pancreas, liver, heart, and skeletal muscle156.
The actions of BDNF in utero are diverse and expansive. As a key mediator of fetal
neurodevelopment, it programs neural structure and connection, setting the stage for future brain
development. In addition to its roles in learning, memory, and behaviour, BDNF is also
intertwined with metabolic health and energy status.
1.3.4 BDNF, Neuroinflammation, and Neuroprotection
In addition to neuronal expression, BDNF is secreted from and regulated by microglia157–
159

. Apart from facilitating synaptic refinement, the primary function of microglia is monitoring

and responding to damage-associated proteins and inflammatory cytokines in the neuronal
environment49,158.

22

Traditional classification defines microglia as either “resting” or “activated”160. Resting
microglia have long ratified processes and small cell bodies, which are ideal for their
surveillance function160. When a pathogen or cytokine is detected, these microglia will become
activated; the cell body swells and processes retract as the cell begins releasing inflammatory
cytokines160. This traditional classification fails to account for the broad range of functions
attributed to activated microglia. More recent literature proposes that activated microglia be
divided into two classes, pro-inflammatory (M1) and anti-inflammatory (M2) activated
microglia49,158. As the name suggests, pro-inflammatory microglia release pro-inflammatory
cytokines that recruit and activate microglia at the site of damage, while anti-inflammatory
microglia mediate anti-inflammatory functions through cytokines and various neurotrophic
factors, including BDNF49,158. The M1 class produces ROS, and these cells express a greater
number of antigen-presenting receptors49. The M2 class includes a broader range of activation
states that are differentiated by their receptor profiles, cytokine production, chemokine secretion,
and overall function49. Collectively this group regulates anti-inflammatory functions such as
cellular clean-up, tissue remodelling, and angiogenesis49.
For healthy tissue repair, acute pro-inflammatory activation is followed by antiinflammatory activation49. BDNF produced by microglia acts as a mediator in this secondary
response. Following tissue damage induced by local ischemia, BDNF is suspected to promote
post-lesion plasticity, and attenuating BDNF levels reduces recovery of function following acute
brain injury158,161–163. Even during the peri-natal period, BDNF is capable of counteracting acute
hypoxic-ischemic brain injuries164,165.
A continuous influx of systemic inflammatory cytokines or failure to transition into M2
activation may lead to a sustained pro-inflammatory state with the continued presence of ROS
and pro-inflammatory cytokines49. Pathological neuroinflammation of this nature causes severe
detriment to cognitive function as it leads to neurodegeneration. Unlike acute inflammation
where BDNF may become upregulated, chronic inflammation appears to suppress BDNF and its
TrkB receptor104,166,167. This in turn may also be an attributing factor to the damage induced by
chronic neuroinflammation104.
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Taken together, the regulated release of BDNF from activated microglia is a mechanism
underlying tissue repair following acute damage and inflammation; however, prolonged
neuroinflammation suppresses BDNF expression and signalling.
1.3.5 Impact of Environmental Stressors on BDNF
Similar to BDNF expression in the placenta, neural expression is sensitive to various
forms of environmental stimuli, including stress, physical activity, brain injury, and diet104.
While BDNF likely has protective effects in combatting the detrimental effects of acute stressors,
chronic stressors have been found to impair BDNF expression and signalling. These effects are
largely concentrated at the hippocampus, which is both a site of abundant BDNF expression and
a brain structure often targeted by extended exposure to environmental stressors46,168.
While much of the literature points to downregulation in its expression, the exact impacts
of chronic stress on BDNF-related pathways are likely dependent on the animal model, the type
of stress, and the duration exposure169. Chronic inflammation, intermittent hypoxia, and both
physiological and psychological forms of stress have been found to downregulate BDNF or its
signalling pathway in the hippocampus across various murine and non-human primate
models34,50,154,170–173. Moreover, these downregulations were associated with impaired synaptic
plasticity, decreased hippocampal neurogenesis, increased hippocampal atrophy, altered
behaviour, and cognitive impairment34,50,170.
Just as environmental stressors can impact the expression of BDNF in the adult brain, so
too can they influence its expression in the fetal brain when encountered during the prenatal
period. The hippocampus remains a major target of the damage induced by prenatal stress and it
has been postulated that the vulnerability of the hippocampus may be attributed to alterations in
BDNF signalling174. Both physiological and psychosocial forms of maternal stress during
pregnancy, including maternal nutrient restriction, placental insufficiency, chronic hypoxia,
social isolation, and variable unpredictable stress, have been associated with reduced expression
of BDNF in the fetal hippocampus in multiple rodent models, including the guinea pig174–178. In
some of these studies, the effect persisted into offspring adulthood, communicating long-term
deficits in brain structure and function174,176,177. For example, rats exposed to chronic
unpredictable prenatal stress showed decreased BDNF expression, reduced hippocampal cell
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proliferation, and increased apoptotic signalling, thus reducing hippocampal volume174,176.
Moreover, this reduction was paralleled by increased memory impairment in adult offspring176.
More insidious forms of systemic stress, such as those related to energy status and
metabolic health, have also been found to regulate BDNF expression and signalling. Both
diabetes and obesity have been associated with reduced levels of BDNF in humans and rodent
models, although it is suspected that impaired BDNF expression is both a contributing factor to,
and a by-product of, metabolic dysfunction30,48,179,180. Independent of metabolic dysfunction,
lifestyle factors such as diet and exercise that impact energy status also influence BDNF
signalling. Multiple studies have suggested that diets high in saturated fats and/or simple sugars
reduce hippocampal BDNF levels, impede its signalling, and alter cognitive function47,181–184. In
experimental models, WD feeding for as little as two months reduced hippocampal expression of
BDNF and its downstream effectors of neurogenesis and synaptogenesis, which coincided with
impaired spatial learning performance in rodents and non-human primates47,181,184. Moreover, the
WD was found to worsen cognitive outcomes following brain injury or sleep deprivation with
reduced learning performance that matched the reduction in BDNF signalling in rat models182,183
Much like other maternal stressors, the impacts of maternal metabolic dysfunction and
WD consumption are not limited to the mother. The extent to which these forms of maternal
stress extend to BDNF expression in the fetal brain is less well described; however, a similar
reduction in BDNF expression has similarly been reported in the fetal rat hippocampus following
a high-fat maternal diet, which was also linked to worsened learning performance
postnatally97,140.
Detriments associated with this dietary pattern are likely due to the specifics of its
macronutrient composition. While the saturated fats and refined sugars characteristic of the WD
suppress BDNF expression, omega-3 fatty acids appear to mitigate this effect in rats181. The
beneficial impact of omega-3 fatty acids on hippocampal BDNF expression has also been noted
in the fetal mouse brain following maternal docosahexaenoic acid (omega-3) supplementation185.
Positive effects on BDNF expression have also been attributed to exercise, which has an impact
so striking that it has been proposed as a non-invasive way to mimic the effects of direct BDNF
administrations126,186. This offers greater support to suggest that BDNF is highly related—
positively and negatively—to metabolic health and energy status.
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Hippocampal BDNF expression and signalling, and consequently cognitive function, are
impacted by a broad range of environmental conditions, that include diet and metabolic status. In
the context of pregnancy, maternal metabolic health and dietary patterns may then communicate
neurological deficits through alterations in BDNF expression.

1.4 Rationale, Hypothesis, And Objectives
1.4.1 Rationale
The increasing availability of cheap processed foods has made the WD widely accessible,
resulting in its habitual consumption. The rise in WD popularity is paralleled by increasing rates
of obesity and metabolic dysfunction42. This is unsurprising given the association of habitual
WD consumption with the risk of various cardiovascular and metabolic diseases, including
NAFLD42. While prevalent across society, this dietary pattern is of particular concern for the
pregnant population given that many of these metabolic outcomes convey an increased risk of
pregnancy-related complications187–189.
Research investigating the impact of maternal overnutrition during pregnancy is often
focused on obesity, irrespective of overall metabolic health109. This is problematic because there
is strong evidence to suggest that under the broad term of obesity are two classes of individuals:
the metabolically unhealthy and the metabolically healthy, defined based on the
presence/absence of other metabolic morbidities (impaired glucose tolerance, dyslipidemia,
hypertension, and systemic inflammation)15,16,18,190. Analogous classifications exist amongst a
lean population, with some possessing equal or greater metabolic and cardiovascular risks than
those who are metabolically healthy and obese15,16,18,190. Energy-rich diets are associated with the
development of metabolic dysfunction in both obese and non-obese individuals, but typically
only the obese are captured by most study designs109. Consequently, it is difficult to identify the
risks associated with such a dietary pattern, independent of obesity. This represents a major gap
in the research as ~20% of the population is estimated to fall into this lean metabolically
unhealthy classification and in some conditions, such as NAFLD, this lean phenotype sustains a
greater risk of further metabolic dysfunction than its obese counterpart15,18,24. Collectively this
highlights the importance of understanding the risks associated with maintaining a lifestyle (ex,
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habitual WD consumption) that perpetuates both lean and obese metabolically unhealthy
phenotypes—a topic on which research is scarce, particularly in the context of pregnancy.
The DOHaD hypothesis posits that adverse events experienced in utero are capable of
programming fetal development such that it alters the long-term health outcomes of the
individual109,191. While initial research was focused on the implications of maternal stressors on
fetal metabolic health outcomes, more recent research has found similar detriments in fetal
neurodevelopment73,95,102,192. Brain development is resource-intensive, demanding nutrients and
trophic factors from the mother and placenta to support and direct its processes95. Consequently,
aberrations in placental development and function likely link maternal stressors to the cognitive
impairment noted in their offspring. The hippocampus is particularly vulnerable to maternal
stressors during pregnancy168. As a mediator of learning, memory, and behaviour, alterations in
its development may explain cognitive abnormalities noted in offspring exposed to adversity in
utero35,168.
Metabolic dysfunction, such as that associated with habitual WD consumption, is an
example of intrauterine adversity that may convey detriment to the fetus. In addition to fostering
chronic low-grade inflammation and ROS production, the WD alters energy balance, all of
which have been shown to interfere with fetal growth and neurodevelopment93,102,192. While the
exact mechanism behind this relationship remains unknown, BDNF has emerged as a possible
candidate linking maternal energy status with placental and fetal brain development as its
expression in both tissues is impacted by both maternal under- and over-nutrition97,112,193. Once
again, studies focused on maternal over-nutrition often fail to capture the subset of metabolically
unhealthy individuals who are lean, instead focusing on the consequences of diet-induced
maternal obesity97,112. Consequently, it is not clear whether BDNF expression in the placenta or
the brain is subject to regulation by the WD, independent of obesity.
The impact of such changes could be severe. BDNF plays a formative role in the
development of both tissues, supporting cell growth and proliferation128,148. Postnatally, BDNF
continues to support learning and memory through its effects on hippocampal neurogenesis and
synaptogenesis, and to facilitate tissue remodelling following neuroinflammation through its
microglia-mediated release148,152,153. It follows that a reduction in BDNF expression in either the
placenta or the brain in utero may impact their structural and functional development, and in the
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brain specifically, may convey long-term changes to the offspring’s cognition. Understanding the
relationship between placental BDNF expression and that of the fetal hippocampus is valuable
because placental expression at term may serve as a non-invasive indicator of its relative
expression in a newborn's brain, potentially indicating risk of future cognitive dysfunction.
Taken together, the present research is focused on understanding the impact of adverse
intrauterine conditions, specifically WD-induced metabolic dysfunction, on placental
development and fetal neurodevelopment. Studies of this nature far and few between; of those
that have previously been conducted, clinical applicability is often hindered by limitations of the
animal model and their exclusive focus on the obese phenotype. The guinea pig is considered a
superior model of human pregnancy and neurodevelopment due to similarities in placental
structure and its relatively long gestational period (~68 days)80,194. Unlike other rodent models,
guinea pigs give birth to precocial young, meaning that extensive neurodevelopment occurs in
utero and is thus more susceptible to pregnancy conditioning like maternal dietary patterns80.
Additionally, studies have shown the guinea pig’s propensity to adopt a lean NAFLD phenotype
in response to chronic WD consumption, reflecting the elusive lean metabolically unhealthy
phenotype195,196. These features set the guinea pig apart as one of the top models for the
developmental origins of neurological dysfunction, particularly in the context of WD-associated
lean metabolic dysfunction.
1.4.2 Hypothesis
It was postulated that chronic maternal WD exposure, resulting in a lean metabolically
unhealthy phenotype, would alter fetoplacental development in a guinea pig model. Moreover, it
was hypothesized to impact the expression of BDNF in the placenta and fetal brain, potentially
communicating alterations in neurodevelopmental processes such as hippocampal neuro- and
glia-genesis, and microglial activation.
1.4.3 Objectives
The objectives of this work are as follows:
1. To characterize maternal and fetal guinea pig growth characteristics for the body and
select organs in near-term pregnancies featuring chronic maternal WD exposure using
magnetic resonance imaging (MRI) segmentations and weights at collection.
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2. To determine the presence and extent of changes in placental pathology in placentae
of WD-fed mothers using a semi-quantitative method to score placental necrosis and
fibrin thrombi on H&E stained placentae.
3. To determine the presence and extent of change in the relative expression of BDNF in
the placenta and hippocampus of fetal guinea pigs born to WD-fed sows using
Western Blot and immunohistochemistry.
4. To determine the presence and extent of changes in cell proliferation and microglial
activation states in the hippocampal region of fetal guinea pigs born to WD-fed sows,
using immunohistochemistry to: a) quantify the number of Ki67 (marker of cell
proliferation) positive cells, b) quantify the number of Iba1 (marker of microglia)
positive cells and characterize cell morphology as an indicator of microglial
activation.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Animal Care
2.1.1 Ethics Statement
All animal care protocols and procedures were conducted in accordance with guidelines
and standards of the Canadian Council on Animal Care. The Western University Animal Care
Committee approved Animal Use Protocol (AUP #2019-116; Appendix A) and conducted postapproval monitoring. All investigators understood and followed the ethical principles outlined by
Grundy197 and the study design was informed by ARRIVE guidelines198. A single cohort of
guinea pigs was used for all experiments in this thesis.
2.1.2 Animal Feeding, Breeding, and Pregnancy
The female offspring of commercially bred guinea pigs (Dunkin-Hartley, Charles River
Laboratories, Senneville, QC) were weaned at 15 days of age and housed in individual cages in a
small animal care facility with a 12-hour light-dark cycle and controlled temperatures (20 ± 2°C)
and humidity (30–40%). At weaning, female pups were randomized to either the Control Diet
(CD; TD.110240; Harlan Laboratories, Madison, WI) (n=3) or the Western Diet (WD;
TD.110239; Harlan Laboratories, Madison, WI) (n=13) (Fig 2.1.2-1) (See Table 2.1.2-1 for
detailed nutrient breakdown). WD was designed to represent human WD consumption199.
Kilocalorie density differed between diets (3.4 vs 4.2 kcal/g); however, protein levels were
matched between the diets based on kilocalorie density. Proteins in both diets were supplied by
isolated soy proteins and made up 21.6% and 21.4% of the total kilocalories for CD and WD
respectively. In the CD, carbohydrates accounted for 60% of total kilocalories, containing
sucrose (100 g/kg), cornstarch (354 g/kg), and cellulose (130 g/kg). In the WD, carbohydrates
comprised 33% of total kilocalories, containing greater proportions of sucrose (190 g/kg) as well
as the addition of straight fructose (65g/kg). In the CD, fats made up 18.4% of the total
kilocalorie density and were derived from soybean oil (60 g/kg), with the following fatty acid
distribution (% total fats): 16.7% saturated fatty acids (SFA), 22.2% monounsaturated fatty acids
(MUFA), and 61.1% polyunsaturated fatty acids (PUFA). Fats in the WD were sourced from a
combination of coconut oil (95 g/kg), cocoa butter (50 g/kg), and lard (55 g/kg), making up 33%
of total kilocalorie density derived largely from SFAs (69.6%) and MUFAs (26.1%), rather than
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PUFAs (4.3%). In addition, the WD contained cholesterol (2.5g/kg). From the point of weaning,
animals were weighed twice weekly and total feed consumption was monitored daily.
The estrous cycles of sows were tracked. A nulliparous female found in estrous was
placed in a breeding cage with a male for ~48-72 hours until the vaginal membrane was closed.
Pregnancies were then confirmed 18-25 days later by ultrasound. The day prior to vaginal
membrane closure was considered the day of conception. Animals that were unsuccessful at
conceiving were rebred at their subsequent estrous cycle(s). Age of sows at conception averaged
(mean ± SEM) at 139 ± 10.21 days for CD animals and 163 ± 9.6 days for WD (difference in age
was not significant between groups). A second ultrasound was performed on gestational day 5760 to confirm litter size prior to MRI and subsequent tissue collection. MRIs were conducted at
day 60 of pregnancy. Animals were sacrificed by CO2 asphyxiation on gestational day 65 (term
~68 days)200.

A

Figure 2.1.2-1. Macronutrient breakdown of (A) Control diet and (B) Western diet.
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Table 2.1.2-1 Composition of the experimental Control diet (CD) and Western diet (WD)
Item
Main ingredients (g kg−1)
Isolated soy protein
L-Methionine
Sucrose
Fructose
Corn starch
Maltodextrin
Cellulose
Soybean oil
Cocoa butter
Lard
Coconut oil
Cholesterol
Vitamin Mix Teklad (40060)
Vitamin C, L-ascorbyl-2-polyphosphate (35%)
Folic acid
Calcium phosphate dibasic
Potassium citrate, monohydrate
Magnesium oxide
Potassium chloride
Sodium chloride
Calcium carbonate
Ferric citrate
Manganese sulfate, monohydrate
Zinc carbonate
Cupric sulfate
Potassium iodate
Chromium potassium sulfate, dodecahydrate
Sodium selenite, pentahydrate
Ammonium paramolybdate, tetrahydrate

CD∗
(TD.110240)
210
2.47
100
—
354
93
130
60
—
—
—
—
10
0.61
0.008
17.66
9.85
2.63
3.29
1.64
4.1
0.33
0.164
0.05
0.0164
0.0008
0.008
0.0008
0.0002

WD*
(TD.110239)
255
3
190
65
—
93
130
—
50
55
95
2.5
12.3
0.75
0.01
21.5
12
3.2
4
2
5
0.4
0.2
0.06
0.02
0.001
0.01
0.001
0.0003

Chemical composition
Protein (% kcal)
Fat (% kcal)
Carbohydrates (% kcal)
Energy (kcal g−1)

21.6
18.4
60
3.4

21.4
45.3
33.3
4.2

Fatty acid composition (% of total fatty acids)
Lauric acid (C12:0)
Myristic acid (C14:0)
Palmitic acid (C16:0)
Stearic acid (C18:0)
Oleic acid (C18:1cis9)
Linoleic acid (C18:2n−6)
α-Linoleic acid (C18:3n−3)

—
—
11
4
23.5
53.4
8

23.12
8.83
17.32
13.24
24.4
4.2
0.03

∗Diets were formulated in the Harlan Laboratories (Madison, WI, USA).
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2.1.3 Tissue Collection and Sample Preparation
At collection maternal bodies and livers were weighed immediately upon sacrifice (CD:
n=3, WD: n=13). Placentae were weighed and then sectioned in half longitudinally; half was
immediately flash-frozen in liquid nitrogen for use in western blotting experiments, while the
second half was prepared for fixation for use in immunohistochemistry. Fetuses were weighed
and sexed before undergoing full necropsy (CD: n=9, WD: n=24). Fetuses that showed evidence
of in utero demise (degrading brain and/or evidence of reabsorption) were excluded from the
collection. Fetal brains were weighed and coronally sectioned at the optic chiasm through the
mamillary body. Fetal brains and placentae were immersion fixed using 4% paraformaldehyde
for 24 hours, rinsed 3X with phosphate-buffered saline (PBS) for 2-hour intervals, and then
washed with 70% ethanol for 14 days. The blocks were processed in paraffin wax, embedded,
and sectioned using a rotary microtome at a thickness of 5 μm. Tissue sections were then
mounted on 1.5mm Superfrost Plus Slides (VWR Scientific, Westchester, PA).
To ensure fetal hippocampal structures were preserved in all sections, a single section
from each caudal brain block was stained with hematoxylin and eosin (H&E). Using the
Comparative Mammalian Brain Collection – Guinea Pig (University of Wisconsin) as a
reference, each brain was systematically re-sectioned and stained with H&E until the correct
brain region (#840; Fig 2.1.3-1) was achieved.

33

Figure 2.1.3-1. Representative image of coronally-sectioned guinea pig brain stained with Nissl.
Obtained from Comparative Mammalian Brain Collection created by the University of
Wisconsin.

2.2 Magnetic Resonance Imaging
2.2.1 Maternal Magnetic Resonance Imaging
All magnetic resonance imaging (MRI) was performed by members of the McKenzie
Laboratory as described by Sinclair, et al on ~day 60 gestation196. Images were used to quantify
body and tissue volumes, as well as hepatic fat fractions for both maternal and fetal animals.
Briefly, animals were fasted for 2 hours prior to MRI. Glycopyrrolate (0.01mg/kg body
weight) was administered to animals 30 minutes prior to MRI via subcutaneous injection to
reduce saliva production and minimize the risk of asphyxiation while anesthetized. Following
glycopyrrolate administration, sows were anaesthetized using a constant flow of 4.5% isoflurane
and then maintained with 1.5-2.5% isoflurane. Sows were supplied with 100% O2 (2L/min) for
the duration of the experiment. Vital signs (heart rate, electrocardiogram waveform, respiratory
rate, respiratory waveform, oxygen saturation, and temperature) were monitored throughout the
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experiment using an animal monitoring kit (Small Animal Instruments, Stony Brook, NY). The
core body temperature of the sows was maintained with a water-bath system circulating heated
water beneath them. Foam earplugs were inserted, and protective lubricant was applied to both
eyes.
A series of anatomical T1 and IDEAL water-fat MRI images were collected with a 3
Tesla MRI (MR750, General Electric, Waukesha, WI, USA) as described by Sinclair et al196. For
T1-weighted gradient-echo images (repetition time/echo time [TR/TE] = 5.1ms/2.4ms, flip angle
= 15°, number of averages = 4, total scan time ~ 7min) were acquired with 0.875 × 0.875 mm2
in-plane spatial resolution and 0.9 mm slice thickness. IDEAL water-fat images (TR/ΔTE =
9.4ms/0.974ms, 6 echoes, flip angle = 4°, number of averages = 4, total scan time ~ 13min) were
also collected for each guinea pig with 0.933 × 0.933 mm2 in-plane spatial resolution and 0.9
mm slice thickness. IDEAL images were accelerated with parallel MRI by a factor of 1.75 in
both the phase and slice directions. For all images, the field of view was centred on the sow’s
abdomen, ensuring all fetoplacental units were in view. Following MRI, the sows were
monitored while recovering from anesthesia, after which they were returned to their cages.
2.2.2 MRI Image Analysis
Manual, full-volume segmentation was performed on T1 anatomical images and water-fat
images using 3D Slicer software (version 4.9.0)201 (Figure 2.2.2-1). Whole-body and organ
volume measurements for maternal (CD: n=3, WD: n=13) and fetal populations (CD: n=11, WD:
n=26) were obtained from T1 anatomical images, while maternal visceral adipose tissue (VAT)
and fetal total adipose tissue (TAT) volumes were derived from water-fat images. Hepatic
proton-density fat fractions (HPFF), representing a quantitative measure of the fraction of
hepatic tissue composed of triglycerides, were likewise acquired202. To obtain the HPFF, the
liver was segmented using anatomical images and then triglycerides were quantified using waterfat images.
Fetuses that showed evidence of intrauterine demise (3 fetuses from the WD group) were
excluded from analyses. Sex was not a variable considered in the fetal analysis because it was
unidentifiable at the time of MRI.
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Figure 2.2.2-1. Whole-body segmentation conducted on (A&B) T1 anatomical images and
(C&D) IDEAL water-fat images. Images represent single frames of MRI sequence. Outlined
regions represent whole-body, organ, or tissue volumes. VAT: visceral adipose tissue; F: fetus;
P: placenta; TAT: total adipose tissue.

2.3 Placental Pathology Scoring
2.3.1 Hematoxylin and Eosin Staining
Following deparaffinization, placental sections were rinsed for 5 minutes in pure water
and then immersed for 10 seconds in Harris modified hematoxylin stain (Fisher Scientific,
Hampton, NH). The stain was differentiated in 1% acid ethanol (2 mL HCl + 198 mL 70%
ethanol) for 1 second and then immediately rinsed under running water for 1 minute. Tissue
sections were then stained with eosin (1% eosinY in 95% ethanol and 0.5% glacial acetic acid;
Fisher Scientific, Hampton, NH) for approximately 1 second. The tissue sections were then
dehydrated and DPX mountant was applied before mounting the slides with a coverslip.
2.3.2 Pathology Scoring
To characterize the health of placental tissue, H&E stained sections of placentae were
semi-quantitatively analyzed at multiple magnifications by an experienced pathologist. The
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scoring system used was established for the present study, although similar schemes have
previously been used to characterize placental pathology203,204. To eliminate any experimental
bias, the scorer was blinded to the diet group of each animal.
Sections were scored from 0 to 3 for the distribution and the degree of necrosis or fibrin
thrombi (Table 2.3.2-1). Individual scores of distribution and degree were summated to yield a
necrosis score and a fibrin score, each ranging from 0 to 6. The total pathology score represents
the sum of necrosis and fibrin scores, in which a score of 0 represents a healthy placenta and a
score of 12 represents a placenta with wide-spread, severe necrosis, and fibrin thrombi.

Table 2.3.2-1. Pathology Scoring System
Score

0

1

2

3

Degree

Minimal

<25%

25-50%

>50%
Multifocal to

Necrosis
Distribution

None

Focal

Multifocal

coalescing or
locally extensive

Fibrin

Frequency

None

1-2

<5

>10

thrombi

Degree

None/minimal

Small, discrete

Large

Extensive area

2.4 Western Blotting
2.4.1 BDNF Western Blot Analysis
Flash-frozen placentae were ground and homogenized in RIPA lysis buffer (50 mM TrisHCl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% Na-deoxycholate, pH 7.4) with protease
and phosphatase inhibitors. Samples were sonicated and then centrifuged at 10,000g for 10 min
at 4°C. The supernatants were collected, and their protein levels were quantified using the Pierce
BCA Protein Assay Reagent Kit (ThermoFisher, Waltham, CA), following the manufacturer's
instructions.
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A sample from each supernatant was mixed with 5X laemmli sample buffer and betamercaptoethanol (BME), and then heated for 10 min at 75°C. From each sample, 30 µg of total
protein were loaded into individual wells of polyacrylamide gels for SDS-PAGE (4% stacking
gel, 10% separating gel). The prepared placental samples were distributed across three gels such
that each gel had samples from both sexes and from both diet groups. One lane of each gel was
loaded with the same pooled sample for subsequent normalization, and another lane from each
gel was left empty to serve as a negative control. Gels were run at 120V until the dye fronts
reached the bottom of gels (~60-90 mins) in 1X running buffer. Once separated, proteins were
transferred onto polyvinylidene difluoride (PVDF) membranes (Amersham Hybond P 0.2 µm
PVDF) using the wet transfer method at 100V for 90 minutes in 1X transfer buffer.
Following protein transfer, membranes were incubated in Ponceau S stain for 5 minutes,
and then rinsed briefly with methanol. The Ponceau S stain binds to protein transferred to PVDF
membranes, which confirms the extent and success of the protein transfer, and visible protein lanes
can then be quantified and used for total protein normalization205. Bands representing total protein

were visualized on ChemiDoc (Bio-Rad Laboratories, Hercules, CA) and show efficient transfer
and allow for total protein normalization.
Membranes were blocked with 5% milk diluted in tris-buffered saline/tween 20 (0.01%)
(TBS-T) for 1 hour at room temperature on a shaker. Blots were then incubated with anti-rabbit
polyclonal BDNF (1:1000; PA5-85730, Invitrogen, Waltham, CA) diluted with 5% milk in TBST overnight at 4°C on an orbital shaker. The following day, blots were probed with horseradish
peroxidase-conjugated anti-rabbit IgG (1:10000; #7074, Cell Signalling Technologies, Danvers,
MA) secondary antibody diluted with 5% milk in TBS-T for 1 hour at room temperature.
Immunoreactive bands were visualized on ChemiDoc (Bio-Rad Laboratories, Hercules,
CA) using electrochemiluminescent substrate Clarity Max (Bio-Rad Laboratories, Hercules, CA)
and ensuring exposure times were kept constant across all blots. A single band was detected at
~14 kDa representing mature BDNF expression. Bands representing total BDNF protein
abundance were quantified using the ImageLab software (Bio-Rad Laboratories, Hercules, CA)
and then normalized by the total protein (Ponceau S stain) as previously described by Sander et
al206.
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2.5 Immunostaining and Image Analysis
2.5.1 BDNF Immunohistochemistry, Image Acquisition, and Analysis
All staining was performed on the same day with the same batch of reagents to limit
staining variability. The tissue sections were deparaffinized in three sequential 5-minute xylene
washes and then rehydrated in a graded series of ethanol washes (2X at 100%, 2X at 90%, and
1X at 70%) for 2 minutes each, followed by running tap water for 5 minutes. Heat-induced
epitope retrieval (HIER) was performed using 10mM Sodium Citrate buffer pH 6.0 in the 2100
Antigen Retriever Device (Aptum Biologics Ltd, Southampton, UK). Following HIER, the
samples were washed in PBS (2X 5mins) and then 3% hydrogen peroxide for 10 minutes to
quench endogenous peroxidase. After two rinses in phosphate-buffered saline (PBS), background
SNIPER (Biocare Medical, Pacheco, CA) was applied to the samples for 7 minutes to reduce
non-specific background staining. Samples were then incubated with anti-rabbit polyclonal
BDNF primary antibody (1:500; PA5-85730, Invitrogen, Waltham, CA) overnight at 4℃ in a
covered humidity chamber. Antibodies were diluted using DAKO diluent (Agilent Technologies,
Santa Clara, CA) and for one slide diluent was substituted for primary antibody to serve as a
negative control.
The following day, samples were rinsed in PBS and then incubated with ImmPRESS
anti-rabbit horseradish-peroxidase polymer solution (MP-6401-15, Vector Laboratories,
Burlington, ON) for 45 minutes at room temperature in a covered humidity chamber. Slides were
rinsed with PBS and bound antibody was visualized by incubating slides with brown
diaminobenzidine (DAB) chromogen (Sigma Aldrich, St. Louis, MO) for 6 minutes. After a
rinse in tap water, samples were counterstained with brief (1 minute) exposure to modified
Mayers Hematoxylin stain, after which they were rinsed again with tap water. Samples were then
dehydrated in an increasing series of ethanol washes (2X at 70%, 2X at 90%, 2X at 100%) for 30
seconds each, followed by three 5-minute xylene washes. Slides were immediately cover slipped
with DPX Mountant.
Analyses were conducted on coronal sections at the level of the optic chiasm and
mamillary bodies. Brain regions being analyzed include the CA3 and dentate gyrus of the
hippocampus, along with the thalamus—sites known to express BDNF in abundance46. At each

39

brain region, 4-6 different high-power field images were captured with the Zeiss AxioImager Z1
microscope (Carl Zeiss Canada Ltd, North York, ON) using a 40X oil objective. Identical
illumination settings were used for all captured images to ensure an accurate comparison.
Image analysis was performed using Image-Pro Premier 9.2 software (Media Cybernetics
Inc., Rockville, MD) ensuring that the analyst was blind to the diet group of each animal. Images
were analyzed based on the percent area stained and integrated optical density, which considers
both the area stained as well as the average intensity of the pixels. A threshold established
through the smart selection feature was used to detect areas of positive staining based on
intensity and colour. Thresholds were tested on a variety of images including negative control to
ensure specificity and then applied uniformly to all images to obtain data. Software was
calibrated to specific magnification, prior to analysis.
2.5.2 Hematoxylin Staining, Image Acquisition, and Analysis
All staining was performed on the same day with the same batch of reagents to limit
staining variability. The tissue sections were deparaffinized as described above. Samples were
stained for 90 seconds with modified Mayers Hematoxylin stain, after which slides were washed
in tap water. Samples were then dehydrated and mounted as previously described for BDNF
immunohistochemistry.
Analyses were conducted on coronal sections at the level of the optic chiasm and
mamillary bodies. Brain regions being analyzed include the CA1, CA3, dentate gyrus of the
hippocampus, along with the thalamus. At each brain region, 4-6 different high-power field
images were captured with the Nikon Eclipse Ti2E Inverted Deconvolution Microscope (Nikon
Canada, Mississauga, ON) using a 60X oil objective. Identical illumination settings were used
for all captured images to ensure an accurate comparison.
Image analysis was performed using Image-Pro Premier 9.2 software (Media Cybernetics
Inc., Rockville, MD) ensuring that the analyst was blind to the diet group of each animal. Cells
were counted semi-automatically with a threshold established through the smart selection feature
that was trained to detect areas of hematoxylin staining based on intensity and colour. Software
was calibrated to specific magnification, prior to analysis.
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2.5.3 Ki67 Immunohistochemistry, Image Acquisition, and Analysis
All staining was performed on the same day with the same batch of reagents to limit
staining variability. The Ki67 antigen is a marker of cell proliferation expressed by cell nuclei in
the active phase of the cell cycle that has been previously used to quantify neurogenesis207.
Ki67 immunostaining was performed as described for BDNF immunohistochemistry with
the following modifications: HIER was performed using 10mM Tris-EDTA buffer pH 8.0, and
monoclonal mouse anti-human Ki67 primary antibody (1:4000; IR626, Agilent Technologies,
Santa Clara, CA) and ImmPRESS anti-mouse horseradish-peroxidase polymer solution (MP7422-15, Vector Laboratories, Burlington, ON) were used as primary and secondary antibodies,
respectively.
Analyses were conducted on coronal sections at the level of the optic chiasm and
mamillary bodies. The brain regions being analyzed include hippocampal regions CA1, CA3,
and dentate gyrus, as the hippocampus is a primary site of neurogenesis88. At each brain region,
4-6 different high-power field images were captured with the Zeiss AxioImager Z1 microscope
(Carl Zeiss Canada Ltd, North York, ON) using a 40X oil objective. Identical illumination
settings were used for all captured images to ensure an accurate comparison.
Image analysis was performed using Image-Pro Premier 9.2 software (Media Cybernetics
Inc., Rockville, MD) ensuring that the analyst was blind to the diet group of each animal. Images
were analyzed based on the number of Ki67-positive cells per mm2. A threshold established
through the smart selection feature was used to detect positive staining based on intensity,
colour, and morphology. Thresholds were tested on a variety of images, including the negative
control, to ensure specificity, and then applied uniformly to all images to obtain data. Software
was calibrated to specific magnification, prior to analysis. Using calibration, raw data expressing
values per µm2 was scaled to mm2.
2.5.4 Iba1 Immunohistochemistry, Image Acquisition, and Analysis
All staining was performed on the same day with the same batch of reagents to limit
staining variability. Ionized calcium-binding adapter molecule 1 (Iba1) is a protein expressed in
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both the cell processes and soma of microglia cells. As such, the Iba1 marker is commonly used
to study microglial morphology, which is heavily tied to microglial activation state160,208.
The tissue sections were deparaffinized as described for BDNF immunohistochemistry.
Heat-induced epitope retrieval (HIER) was performed using 10mM Sodium Citrate buffer pH 6.0
in the 2100 Antigen Retriever device (Aptum Biologics Ltd, Southampton, UK). Following
HIER, the samples were washed in PBS and then 3% hydrogen peroxide for 10 minutes to
quench endogenous peroxidase. After a phosphate-buffered saline (PBS) rinse, background
SNIPER (Biocare Medical, Pacheco, CA) was applied to the samples for 7 minutes to reduce
non-specific background staining. Samples were then incubated with primary antibody, antirabbit polyclonal Iba1 primary antibody (1:3000; 019-19741, FUJIFILM, College Station, TX)
overnight at 4℃ in a covered humidity chamber. Antibodies were prepared in a solution of 50%
background SNIPER and 50% PBS with horse serum (Vector Laboratories, Burlington, ON).
One slide was incubated with this diluent preparation rather than the primary antibody to serve as
a negative control.
The following day, samples were rinsed in PBS and then incubated with ImmPRESS
anti-rabbit horseradish-peroxidase polymer solution (MP-6401-15, Vector Laboratories,
Burlington, ON) for 45 minutes at room temperature in a covered humidity chamber. Slides were
washed with PBS and then bound antibody was visualized by incubating slides with black
diaminobenzidine (DAB) chromogen (Sigma Aldrich, St. Louis, MO) for 6 minutes. After
subsequent washes in tap water and PBS, slides were incubated with DAPI counterstain (1:300:
Life Technologies, Burlington, ON, Canada) prepared in PBS for 2 minutes at room temperature
with minimal light exposure. Following PBS and tap water washes, samples were dehydrated in
an increasing series of ethanol washes (1X at 70%, 1X at 90%, 1X at 100%) for 15 seconds each,
followed by a 15-second dip in toluene. Slides were immediately cover slipped with DePex
mountant.
Analyses were conducted on coronal sections at the level of the optic chiasm and
mamillary bodies. Brain regions being analyzed include hippocampal regions CA1, CA3, and
dentate gyrus, as well as the corpus callosum and thalamus. A fluorescent channel was used to
visualize DAPI stain and to navigate to brain regions of interest, while a brightfield channel was
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used to capture all images. At each brain region, Z-stack images were taken at 4-6 different highpower fields per brain region with a Zeiss AxioImager Z1 microscope (Carl Zeiss Canada Ltd,
North York, ON) using a 40X oil objective. Illumination settings used for all brain regions were
identical. Each stack of images was converted to a two-dimensional image for subsequent image
analysis.
Image analysis was performed using Image-Pro Premier 9.2 software (Media Cybernetics
Inc., Rockville, MD) ensuring that the analyst was blind to the diet group of each animal. Two
thresholds were established through the smart selection feature. The first threshold identified
positive-staining cell bodies along with attached large processes. The second threshold identified
small processes. Both identified objects based on morphology and intensity of greyscale images.
Thresholds were tested on a variety of images, including the negative controls, to ensure
specificity, and then they were applied uniformly to all images as follows (Fig 2.5.4-1). The first
threshold was used to capture cell bodies and their attached processes. Large processes were
manually segmented, and cell bodies and large processes data were then captured independently.
The second threshold was used to capture small processes that were not attached to a visible cell
body.
Images were analyzed based on the number of Iba1-positive cells per mm2, and by the
morphological feature of positive staining cells. Specifically, cell body size, roundness, and cell
body to process ratio were investigated as measures of microglial activation. Software was
calibrated to specific magnification, prior to analysis. Using calibration, raw data expressing
values per µm2 was scaled to mm2.
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Figure 2.5.4-1. Representative images of ionized calcium-binding adapter molecule 1 (Iba1)
image analysis process on high-power field (40X) Z-stack imaged of the dentate gyrus region of
Control diet brain: (A) original image, (B) collect: cell body, (C) collect: large processes, (D)
collect: small processes. Red outlines reflect Iba1-positive staining area being identified by
software intensity and size threshold. Scale bar = 20µm

2.6 Statistical Analyses
2.6.1 Data Acquisition and Statistical Analyses
Maternal weight at conception was taken prior to breeding, while the maternal weight at
sacrifice was measured prior to fetal collection minus the weights of all respective fetoplacental
units. Litter sizes were based on the number of viable fetuses at collection. Gestational weight
gain represents the difference between maternal weight at sacrifice, weight at conception, and the
weight of all fetoplacental units. Likewise, maternal volumes attained by MRI were normalized
by subtracting the volumes of all fetoplacental units. Three WD fetuses were excluded from all
analyzes because they showed evidence of in utero demise both in MRI images and at collection.
These fetuses could be identified from MRI analyses based on the integrity of their central
nervous system relative to neighbouring fetuses as well as the quality of their placenta209. Two
WD placentae were excluded from BDNF western blot analysis due to improper tissue freezing.
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Three WD brains were excluded from immunohistochemistry analyses due to hippocampal
damage that occurred during tissue sectioning.
All data are presented as group means ± SEM. The normality of data was confirmed
using a Shapiro Wilks test (Graphpad Software, San Diego, CA). To compare between maternal
CD and WD populations a Welch’s two-tailed t-test (Graphpad Software, San Diego, CA) was
used. For all fetal data, a linear mixed model (LMM) emmeans pairwise analysis (RStudio
Software, Boston, MA) was performed averaged over sex to compare between diet groups with
maternal ID as the fixed effect (See appendix for code)210. A LMM was used because it accounts
for a fixed variable that differs within the sample populations—in the present analysis, maternal
ID—that might otherwise confound results. While the sex of fetuses was recorded, the sample
population was not large enough to achieve high statistical power based on power calculations.
For all correlation analyses a Pearson correlation coefficient analysis was performed (Graphpad
Software, San Diego, CA). Statistical significance was assumed when p<0.05 for all analyses.
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CHAPTER 3: RESULTS
3.1 Maternal and fetal population characteristics
3.1.1 Maternal and fetal MRI volume measurements
MRIs were conducted on Control diet (CD) and Western diet (WD) sows around
gestational day 60 to determine the maternal and fetal body and organ volumes. Although not
significant, WD sows had smaller whole-body volumes compared to those in the CD group (CD:
818.40cm2 ± 54.55cm2 vs WD: 720.30cm2 ± 15.33cm2) (Fig 3.1.1-1A). Maternal VAT and liver
volumes were both compared as a percentage of maternal body volume. Maternal VAT volumes
were similar between diet groups (CD: 2.49% ± 0.82% vs WD: 2.83% ± 0.16%) (Fig 3.1.1-1B).
As for the maternal liver, volumes did not differ significantly (CD: 4.56% ± 0.18% vs WD:
5.17% ± 0.32%) (Fig 3.1.1-1C); however, the hepatic fat fraction of the WD sows was
significantly greater than that of the CD sows (p<0.01; CD: 4.33% ± 0.33% vs WD: 7.38% ±
0.88%) (Fig 3.1.1-1D).
Analogous volumetric measurements were also obtained from CD and WD fetuses. Fetal
whole-body volumes did not differ significantly between groups (CD: 56.16cm2 ± 2.57cm2 vs
WD: 65.53cm2 ± 2.06cm2) (Fig 3.1.1-2A). WD placentae were ~34% larger by volume than the
CD placentae (p<0.001; CD: 6.84cm2 ± 1.59cm2 vs WD: 9.19cm2 ± 1.44cm2) (Fig 3.1.1-2B).
Fetal TAT, brain, and liver volumes were all compared as a percentage of fetal body volumes.
Neither TAT volumes (CD: 7.30% ± 0.50% vs WD: 9.56% ± 0.38%), nor brain volumes (CD:
3.11% ± 0.08% vs WD: 3.68% ± 0.22%) were significantly different between the fetal groups
(Fig 3.1.1-2C). Conversely, liver volumes were greater in the WD fetuses compared to the CD
fetuses (p<0.05; CD: 5.17% ± 0.62% vs WD: 7.53% ± 0.26%) (Fig 3.1.1-2C). Additionally, the
fetal WD group had an average hepatic fat fraction that was nearly double that of the CD fetuses
(p<0.01; CD: 6.91 ± 1.00% vs WD: 14.00% ± 0.71%) (Fig 3.1.1-2D).
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Figure 3.1.1-1. Maternal MRI measurements of Control diet (CD) (n=3) compared to Western
diet (WD) (n=13) sows; data present distribution of (A) maternal volume (cm3) normalized by
volume of fetoplacental unit, (B) visceral adipose tissue (VAT) volume relative to maternal
volume (%), (C) liver volume relative to maternal volume (%), (D) hepatic fat fraction (%).**;
p<0.01. Statistical significance of the difference between means determined using Welch’s T
Test. Box plot legend: median (midline), box (25th and 75th percentiles), and whiskers
(extrema).
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Figure 3.1.1-2. Fetal (~60 days) MRI measurements of Control diet (CD) (n=11) compared to
Western diet (WD) (n=26) fetuses; data present distribution of (A) fetal volume (cm3), (B)
placental volume (cm3), (C) tissue-fetal volume ratios expressed as percentage of fetal volume
(%), and (D) hepatic fat fraction (%); * p<0.05, **; p<0.01, ***; p<0.001. Statistical significance
of the difference between means determined using a linear mixed effects model emmeans
pairwise analysis with maternal ID as the fixed effect. TAT: Total Adipose Tissue. Box plot
legend: median (midline), box (25th and 75th percentiles), and whiskers (extrema).
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3.1.2 Maternal and fetal growth measurements
Maternal CD (N=3) and WD (N=13) fed sows underwent full necropsy at gestational day
65. While there was no significant difference between the body weights of CD and WD sows at
conception (CD: 707.0g ± 52.08g vs WD: 665.5g ± 16.01g), nor at sacrifice when normalized by
the weight of their respective fetoplacental units (CD: 803.1g ± 40.11g vs WD: 746.7g ± 14.68g)
(Fig 3.1.2-1A). Similarly normalized weight gain across pregnancy did not differ between
groups (CD: +96.15g ± 19.86g vs WD: +81.20g ± 10.51g) (Fig 3.1.2-1B). Moreover, while not
significant, WD sows had only 1-3 viable pups per litters, whereas CD sows consistently had 3-5
pups per litter (Fig. 3.1.2-1C). The livers of WD sows were ~25% larger by weight compared to
CD sows (p<0.05; CD: 32.62g ± 2.36g vs WD: 40.88g ± 2.10g) (Fig 3.1.2-1D).
While there was no significant difference in body weight between fetuses (CD: 84.92g ±
5.80g vs WD: 88.16g ± 2.89g) (Fig 3.1.2-2A), the placentae of the WD group were ~56% larger
by weight than CD (p<0.01; CD: 4.89g ± 0.42g vs WD: 7.62g ± 0.25g) (Fig 3.1.2-2B). In
addition, the fetal to placental weight ratio, a measure of placental efficiency, was reduced in the
WD group relative to the CD (p<0.001; CD: 17.71g ± 0.77g per g vs WD: 11.78g ± 0.47g per g)
(Fig 3.1.2-2C). All fetal organ weights were analyzed as a percentage of fetal body weight.
While fetal brains did not differ significantly in weight between groups (CD: 2.89% ± 0.15% vs
WD: 2.67% ± 0.10%) (Fig 3.1.2-2D), fetal livers were larger in WD fetuses compared to CD
fetuses (p<0.05; CD: 4.68% ± 0.34% vs WD: 6.69% ± 0.25%) (Fig 3.1.2-2D).
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Figure 3.1.2-1. Maternal growth measurements of Control diet (CD) (n=3) compared to Western
diet (WD) (n=13) sows; data present distribution of (A) body weight at conception and at
sacrifice (g), (B) gestational weight gain (g) normalized by weight of fetoplacental unit, (C) pups
per litter, and (D) liver weight (g). * p<0.05, ***; p<0.001. Statistical significance of the
difference between means determined using Welch’s T Test. Box plot legend: median (midline),
box (25th and 75th percentiles), and whiskers (extrema).
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Figure 3.1.2-2. Fetal (~65 days) growth measurements of Control diet (CD) (n=9) compared to
Western diet (WD) (n=24) fetuses; data present distribution of (A) fetal body weight (g), (B)
placental weight (g), (C) fetal-placental weight ratio expressed as percentage of placental weight
(%), (D) organ-fetal weight ratios expressed as percentage of fetal body weight (%); * p<0.05,
**; p<0.01, ***; p<0.001. Statistical significance of the difference between means determined
using a linear mixed effects model emmeans pairwise analysis with maternal ID as the fixed
effect. Box plot legend: median (midline), box (25th and 75th percentiles), and whiskers
(extrema).
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3.2 Placental Pathology
3.2.1 Placental Pathology Scores
To characterize placental tissue, H&E stained sections of placentae (Fig 3.2.1-1) were
semi-quantitatively analyzed by a certified veterinary pathologist (Dr. Patti Kiser). Necrosis and
fibrin were scored individually on a scale of 0-6 that reflected the severity and distribution of
either feature. Individual necrosis and fibrin scores were summated to establish a total pathology
score for each placenta with 0 representing a healthy placenta and 12 representing a placenta
with wide-spread, severe necrosis, and fibrin thrombi. Although scale was established for this
study specifically, similar scoring schemes have previously been used203,204.
WD placental pathology scores were 5-times higher than that of the CD placentae
(p<0.05; CD: 1.00 ± 0.41 vs WD: 5.08 ± 0.66) (Fig 3.2.1-2). Individually, both fibrin and
necrosis scores were higher in the WD placentae (Fibrin: 2.58 ± 0.37; Necrosis: 0.67 ± 0.29)
compared to CD placentae (Fibrin: 0.67 ± 0.29; Necrosis: 0.33 ± 0.24); however, only the
difference in necrosis scores achieved significance (p<0.05) (Fig 3.2.1-2).
A correlation analysis was performed to understand the relationship between placental
weight and corresponding pathology scores. These data had a significant positive correlation
(p<0.001) with an R value of 0.55 (Fig 3.2.1-3A). The relationship between fibrin and necrosis
scores was also investigated. The two pathology scores had a significant positive correlation
(p<0.0001) with an R value of 0.64 (Fig 3.2.1-3B).
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Figure 3.2.1-1. Representative high-power field of H&E stained placentae in the Control diet
(CD) and Western diet (WD) groups (A&B) at 4X and (C&D) at 40X. Arrow represents region
of necrosis. Scale bars = 1000µm (A&B) and 100µm (C&D).
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Figure 3.2.1-2. Data represent distribution of total pathology scores, fibrin scores, and necrosis
scores of Control diet (CD) (n=9) compared to Western diet (WD) (n=24) placentae. Necrosis
and fibrin were each scored on numerical scale from 0 (no necrosis or thrombi) to 6 (extensive,
wide-spread necrosis or fibrin thrombi) and summated for a total pathology score; * p<0.05.
Statistical significance of the difference between means determined using a linear mixed effects
model emmeans pairwise analysis with maternal ID as the fixed effect. Box plot legend: median
(midline), box (25th and 75th percentiles), and whiskers (extrema).
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Figure 3.2.1-3. Data represent correlation of (A) placental pathology score vs placental weight
(g) and (B) placental fibrin score vs placental necrosis score in total fetal population (n=33).
Statistical significance of the difference between means determined using a Pearson r correlation
analysis. Linear fit lines for all data are shown with 95% confidence intervals. CD: Control diet;
WD: Western diet.
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3.3 BDNF protein expression
3.3.1 Western blot analysis of placental BDNF expression
Western blots were performed to compare the relative level of BDNF protein expression
in the placentae of each diet group. BDNF expression was normalized to total protein detected
using PonceauS stain as described by Sander et al206 (Fig 3.3.1-1A). A single band representing
mature BDNF was detected at 14kDa (Fig 3.3.1-1B). Relative BDNF expression was reduced by
~62% in the placentae of WD fetuses compared to CD placentae (p<0.001; CD: 0.62 ± 0.11 vs
WD: 0.23 ± 0.03) (Fig 3.3.1-1C).
To understand the relationship between placental pathology scores and relative BDNF
expression a correlation analysis was performed. Placental variables showed a significant
(p<0.05) negative correlation with an R value of -0.40 (Fig 3.3.1-1D).
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Figure 3.3.1-1. Data represent (A) distribution of relative placental BDNF expression in Control
diet (CD) (n=9) compared to Western diet (WD) (n=21) placentae and (B) correlation of relative
placental BDNF expression and placental pathology score (n=31); ***; p<0.001. Statistical
significance of the difference between means determined using a linear mixed effects model
emmeans pairwise analysis with maternal ID as the fixed effect, while significance of the
correlation between pathology scores and BDNF expression and a Pearson r correlation analysis,
respectively. Linear fit lines for all data are shown with 95% confidence intervals. Box plot
legend: median (midline), box (25th and 75th percentiles), and whiskers (extrema).
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3.3.2 Immunohistochemical analysis of BDNF in fetal brain
Coronal sections of the fetal brain were immunostained to identify changes in BDNF
protein expression between diet groups. In each region (DG, CA3, thalamus), 4-6 high-power
fields were acquired. BDNF expression was quantified by the percent area stained, and the
integrated optical density, which integrates both the total area stained as well as the pixel
intensity. BDNF immunoreactivity was primarily localized extracellularly near neuronal cells
with the most prominent expression being found in the DG and CA3 regions and moderate
expression found in the thalamus (Fig 3.3.2-1).
BDNF immunoreactivity showed reduced percent area stained in the WD fetuses across
the DG (p<0.001; CD: 10.13% ± 1.31% vs WD: 3.08% ± 0.76%), CA3 (p<0.001; CD: 13.15% ±
1.75% vs WD: 4.60% ± 1.04%), and thalamus (p<0.001; CD: 3.14% ± 0.84% vs WD: 0.77% ±
0.65%) (Fig 3.3.2-2A). Similarly, the integrated optical density was significantly lower in the
WD fetuses across the DG (p<0.001; CD: 1.16x1010 ± 1.58x109 vs WD: 3.66x109 ± 1.05x109),
CA3 (p<0.001; CD: 1.51x1010 ± 2.49x109 vs WD: 5.41x109 ± 1.44x109), and thalamus (p<0.01;
CD: 3.23x109 ± 7.82x108 vs WD: 9.84x108 ± 8.58x108) (Fig 3.3.2-2B)

58

Figure 3.3.2-1. Representative high-power field (40X) images of brain regions exposed to antibrain derived neurotrophic factor (BDNF) immunohistochemistry with hematoxylin counterstain.
Brown staining in the Control diet (CD) (A) dentate gyrus (DG), (B) CA3, and (C) thalamus (T)
and the Western diet (WD) (D) DG, (E) CA3, and (F) T. Brown staining represents BDNF
protein expression. Scale bar = 20µm.
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Figure 3.3.2-2. Data represent the distribution of (A) brain derived neurotrophic factor (BDNF)
area stained (%) (B) integrated optical density in the dentate gyrus (DG), CA3, and thalamus (T)
of Control diet (CD) (n=9) and Western diet (WD) (n=21) fetuses. ***; p<0.001. Statistical
significance of the difference between means determined using a linear mixed effects model
emmeans pairwise analysis with maternal ID as the fixed effect. Box plot legend: median
(midline), box (25th and 75th percentiles), and whiskers (extrema).
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3.4 Cellular changes in fetal brain
3.4.1 Immunohistochemical analysis of Ki67 expression in the fetal hippocampus
Ki67 is a protein expressed by cells that are in the active phase of the cell cycle and it is a
marker that has been previously used to quantify neurogenesis207. To determine the effects of
lifelong maternal WD exposure on fetal hippocampal neurogenesis, Ki67 expression was
quantified in the hippocampus using immunohistochemistry.

In each hippocampal region

(dentate gyrus (DG), CA1, and CA3) 4-6 high-power fields were acquired and Ki67 was
quantified as a positive cell count per mm2 (Fig. 3.4.1-1).
While the mean Ki67-positive cell count was 10-30% lower in the various hippocampal
regions of fetal WD brains compared to those of the CD group, none of the differences were
significant (Table 3.4.1-1).
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Figure 3.4.2-1. Representative high-power field (40X) images of hippocampal brain regions
exposed to anti-Ki67 immunohistochemistry with hematoxylin counterstain. Brown staining in
the Control diet (CD) (A) dentate gyrus (DG), (B) CA1, and (C) CA3; and the Western diet
(WD) (D) DG, (E) CA1, and (F) CA3 represents Ki67 protein expression, a marker of cell
proliferation. Arrows indicate Ki67-positive cells. Scale bar = 20µm.

Table 3.4.1-1. Immunohistochemical analysis of Ki67 in fetal brain

Ki67-positive cell count per mm2
DG
CA1
CA3

Control diet

Western diet

1976.75 ± 222.39
376.93 ± 100.06
414.41 ± 100.46

1760.11 ± 104.71
263.10 ± 34.35
274.25 ± 36.19

Ki67-positive cell count of fetal brains (Control diet: n=9; Western diet: n=21) are presented as
means ± SEM for the dentate gyrus (DG), CA1, and CA3. Statistical significance determined
using a linear mixed effects model emmeans pairwise analysis with maternal ID as the fixed
effect.
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3.4.2 Cell counting
Hematoxylin staining was used to label the cell nuclei in coronal brain sections to
identify changes in cell density between diet groups. In each region (DG, CA1, CA3, thalamus),
4-6 high-power fields were acquired, and cell density was quantified as a cell count per mm2
(Figure 3.4.2-1).
Cell density was decreased across all regions of WD fetal brains compared to those of the
CD group, which includes the DG (p<0.01; CD: 8790.99mm2 ± 669.87mm2 vs WD:
6320.50mm2 ± 226.06mm2), CA1 (p<0.05; CD: 4323.93mm2 ± 474.16mm2 vs WD: 2763.04mm2
± 93.40mm2), CA3 (p<0.05; CD: 3271.33mm2 ± 269.29mm2 vs WD: 2469.49mm2 ± 59.34mm2),
and thalamus (p<0.05; CD: 3543.47mm2 ± 482.81mm2 vs WD: 2084.73mm2 ± 91.62mm2)
(Figure 3.4.2-2).
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Figure 3.4.2-1. Representative high-power field (60X) images of brain regions stained with
hematoxylin in the Control diet (CD) (A) dentate gyrus (DG), (B) CA1, (C) CA3, (D) thalamus
(T) and the Western diet (WD) (E) DG, (F) CA1, (G) CA3, and (H) T. Scale bar = 20µm.
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Figure 3.4.2-2. Data represent the distribution of cell density (per mm2) in the dentate gyrus
(DG), CA1, CA3, and thalamus (T) of Control diet (CD) (n=9) and Western diet (WD) (n=21)
fetuses.*; p<0.05, **; p<0.01 Statistical significance of difference between means determined
using a linear mixed effects model emmeans pairwise analysis with maternal ID as the fixed
effect. Box plot legend: median (midline), box (25th and 75th percentiles), and whiskers
(extrema).
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3.4.3 Immunohistochemical analysis of Iba1 to measure microglial activation
The ionized calcium-binding adapter molecule 1 (Iba1) is a protein expressed by glial
cells that is useful for investigating microglial morphology, which changes from highly ramified
to amoeboid shaped as the cells transition from resting to activated states. Coronal sections of the
fetal brain were immunostained for Iba1. In each region (DG, CA1, CA3, T, and corpus callosum
(CC)) 4-6 high-power field Z-stack images were acquired (Fig 3.4.3-1). Iba1-positive cells were
counted and morphological characteristics indicative of microglial activation, including cell body
to process ratio, circularity, and cell body size, were investigated.
There were no significant differences in the number of Iba1-positive cells between CD
and WD fetal brains in the DG, CA1, CA3, T, or CC. In addition, microglia in the CD and WD
fetal brains showed no significant differences in cell to process ratio, circularity, or cell body size
across any of the brain regions studied (Table 3.4.3-1).
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Figure 3.4.3-1. Representative high-power field (40X) merged Z-stack images of brain regions
exposed to anti-ionized calcium-binding adapter molecule 1 (Iba1) immunohistochemistry. Black
staining in the Control diet (CD) (A) dentate gyrus (DG), (B) CA1, and (C) CA3, (D) thalamus
(T), (E) corpus callosum (CC); and the Western diet (WD) (F) DG, (G) CA1, and (H) CA3, (I)
T, and (J) CC represents Iba1 protein expression, a marker of microglia. Scale bar = 20µm.
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Table 3.4.3-1. Immunohistochemical analysis of Iba1 in fetal brain

Iba1-positive cell count per mm2
DG
CA1
CA3
T
CC
Cell body to process ratio
DG
CA1
CA3
T
CC
Circularity
DG
CA1
CA3
T
CC
Cell body size (pixels)
DG
CA1
CA3
T
CC

Control Diet

Western Diet

94.20 ± 10.79
103.90 ± 8.36
95.19 ± 6.97
80.69 ± 5.80
146.80 ± 18.87

79.54 ± 5.31
93.66 ± 6.27
91.31 ± 6.85
81.89 ± 4.63
148.30 ± 9.95

0.171 ± 0.017
0.177 ± 0.015
0.171 ± 0.011
0.180 ± 0.015
0.158 ± 0.016

0.175 ± 0.0097
0.170 ± 0.0093
0.163 ± 0.0078
0.201 ± 0.014
0.188 ± 0.011

0.519 ± 0.013
0.515 ± 0.014
0.529 ± 0.016
0.519 ± 0.018
0.397 ± 0.023

0.496 ± 0.010
0.479 ± 0.0070
0.491 ± 0.0075
0.493 ± 0.0097
0.394 ± 0.016

547.5 ± 43.01
593.8 ± 41.10
649.7 ± 46.99
631.3 ± 47.02
593.0 ± 36.72

583.4 ± 13.07
598.7 ± 15.61
595.4 ± 15.58
658.3 ± 17.57
589.9 ± 18.16

Microglia (Iba1-positive) cell count and morphological features within fetal brains (Control diet:
n=9; Western diet: n=21) are presented as means ± SEM for the dentate gyrus (DG), CA1, CA3,
thalamus (T), and corpus callosum (CC). Statistical significance determined using a linear mixed
effects model emmeans pairwise analysis with maternal ID as the fixed effect.

67

CHAPTER 4 DISCUSSION
4.1 Impact of Maternal WD on population characteristics
4.1.1 Maternal population characteristics
Habitual WD consumption is associated with metabolic dysfunction in both obese and
non-obese phenotypes42. To investigate the impact of this dietary pattern on a pregnant guinea
pig model, sows were subjected to a diet high in saturated fats and simple sugars from the point
of weening and throughout pregnancy. Their metabolic phenotype was subsequently explored
through MRI and growth measurements collected near term to elucidate differences resulting
from the dietary pattern.
At conception, body weights were comparable between groups. Similarly, when the
weights/volumes of all fetoplacental units were accounted for, body weight and volume did not
differ between the groups. While these measurements suggest both groups maintained a lean
phenotype, these measurements alone offer little indication of internal body composition. Further
investigation found that the diet groups showed no significant differences in VAT. Conversely,
WD-fed sows had larger livers by weight and volume. These measurements were accompanied
by elevated hepatic proton density fat fractions, suggesting an increased proportion of the hepatic
tissue was comprised of lipid. While the triglyceride content of these livers was not analyzed in
this study, previous reports from our lab have reported elevations in the hepatic triglyceride
content of WD-fed guinea pigs195. Taken together these findings implicate hepatic triglyceride
accumulation as a probable cause of the current increases in liver weight and volume noted in the
WD sows. This type of hepatic lipid accumulation is reflective of NAFLD, a prominent indicator
of metabolic dysfunction that communicates the further risk of metabolic disease, even in a lean
phenotype15. Based on these features, the maternal WD-fed population phenotype can be
classified as lean and metabolically unhealthy, specifically reflecting lean NAFLD15.
While diets high in saturated fats and simple sugars are often associated with an obese
phenotype, similar reports implicating the WD with hepatic lipid accumulation in the absence of
obesity have also been described195,211,212. It is speculated that these findings may be attributable,
at least in part, to the high proportion of fructose found in the WD. Dietary fructose, sucrose, and
high-fructose corn syrup have all demonstrated a tendency of inducing hepatic lipid
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accumulation in various experimental animal models and humans213–218. These findings have also
been observed in the absence of weight gain and even when total calories were restricted213,214.
In the small intestine, fructan (polymer of fructose) and sucrose (disaccharide of glucose
and fructose) molecules are cleaved to release free fructose monosaccharides219. Following its
absorption through transporters on the intestinal epithelium, fructose enters the portal system and
is directly transported to the liver where it is metabolized220. Unlike glucose, only a small
fraction of fructose enters the systemic circulation as it is almost completely extracted from the
portal blood upon its first pass220. The primary step of fructose metabolism is its phosphorylation
by ketohexokinase (KHK), which has no negative feedback system219. Unlike glucose
metabolism, fructolysis bypasses enzyme-mediated (phosphofructokinase) regulation, allowing it
to occur at a far faster rate219. The product of fructolysis, a trios phosphate intermediate, may
then enter gluconeogenesis, lipogenesis, or oxidation pathways219. It follows that fructose greatly
increases the availability of intrahepatic carbohydrate stores and promotes a shift towards
carbohydrate oxidation, which results in reduced fatty acid oxidation220. Diets high in fructose
result in significant amounts of carbohydrates entering glycolytic pathways, and thus an excess
of glycolytic intermediates and by-products, which may then be used as substrates for de novo
lipogenesis at the liver219. In addition to acting as a substrate for hepatic de novo lipogenesis,
chronic fructose consumption also induces hepatic lipogenic programs, further promoting the
accumulation of hepatic triglycerides219,220. Moreover, the metabolism of fructose by KHK
greatly decreases the ATP:AMP ratio, resulting in the rapid production of uric acid and
consequently, hepatotoxicity that drives progression of NAFLD to NASH219.
Despite its propensity for promoting the development and progression of NAFLD,
fructose may have opposing actions on peripheral adipose tissue. In rats specifically, an overload
of dietary fructose has been found to increase the release of free fatty acids from peripheral
adipose tissue into the bloodstream, allowing them to be taken up by hepatocytes and stored
within the liver as triglycerides221. Moreover, the combination of saturated fats and refined
sugars, like sucrose and added fructose, have been associated with hyperinsulinemia and insulin
resistance 222. While insulin typically has an anti-lipolytic effect, insulin resistance—particularly
in adipose tissue—can lead to dysregulated lipolysis in peripheral tissues, thus increasing the
supply of free fatty acids arriving at the liver220. Adipocyte insulin resistance is similarly related
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to the development of VAT220. Although the present findings were not significant, greater levels
of VAT were noted in WD sows. This is of note because VAT releases free fatty acids directly
into the portal circulation, offering a direct path to the liver220.
These findings highlight the often-insidious nature of the metabolic dysfunction resulting
from habitual WD consumption, supporting the concept that a lean phenotype does not equate to
superior metabolic health. Moreover, these findings reflect adverse alterations in the maternal
environment which, based on the robust literature surrounding the DOHaD hypothesis, are
expected to confer metabolic or cognitive deficits to the future offspring. Maternal NAFLD
specifically is a strong risk factor for both adverse maternal and perinatal outcomes188.
4.1.2 Fetal population characteristics
In addition to investigating maternal phenotypes, fetal (65 days) MRI and growth
measurements were similarly analyzed to characterize the impact of maternal WD consumption
on the gross development of the fetus. Interestingly, the fetal WD population mirrored the lean
NAFLD phenotype of their mothers. There was no difference in fetal size (by weight or
volumes), nor in TAT; however, the livers of WD fetuses were larger and showed greater levels
of intrahepatic triglyceride accumulation as measured by the proton density fat fraction.
These findings may be the result of primitive adaptive mechanisms regulating nutrient
flow between mother and fetus. The delivery of nutrients to the fetus is influenced by multiple
factors including umbilical blood flow, available surface area for exchange, placental
metabolism, concentration gradients, and nutrient transporter expression223. In addition to
increasing the concentration gradient of nutrients between mother and fetus, maternal
overnutrition (obesity, hyperglycemia, energy-dense diets) has also been shown to alter the
expression of placental nutrient transporters altering nutrient availability to the fetus223,224.
Mismatches in materno-placental nutrient supply and fetal nutrient demand affect the
distribution of umbilical venous blood flow, such that it preferentially delivers nutrients to either
the fetal brain or liver, eliciting changes to fetal body composition225. In environments with
fewer resources than those of the current developed world, these mechanisms served to optimize
fetal development; however, under conditions of abundant nutrient supply (obesity or energyrich diets), these same mechanisms are speculated to promote prenatal fat deposition to preserve
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nutrient supply and buffer brain development from possible nutrient restriction postnatally225.
Much like humans, guinea pigs do not start laying down adipose tissue until later in gestation80.
Given the chronic nature of maternal overnutrition in the present study, it is possible that during
early pregnancy excess nutrients are being deposited findings preferentially in the liver and other
organs196,225. These present findings are supported by the previous works of our collaborators and
others who have similarly reported that maternal diets high in fat and/or refined sugar during
pregnancy were related to increased lipid accumulation in the liver either at birth or
postnatally63,72,196,226,227.
Collectively, these studies along with our present findings underscore the severe
metabolic risks associated with maternal WD consumption independent of obesity and highlight
the importance of maternal diet in programming fetal metabolic health, seeing as fetal hepatic
lipid accumulation increases the individual’s risks of various cardiometabolic diseases17.

4.2 Placental development
4.2.1 Placental growth
The placenta acts as an interface between mother and fetus that regulates communication
and is critical in supporting the development of the fetus. As such, placental MRI and growth
measurements were assessed, alongside the maternal and fetal population characteristics
described above. Maternal WD consumption was associated with increased placental volumes
and weights at collections. Presumably, this increase in placental size was a result of increased
nutrient availability during critical periods of placental development.
The impact of maternal diet on placental size has been investigated in other animal
models; however, their results are often inconsistent due to variability in model animal/strain,
duration of diet exposure, and the specific compositions of both control and experimental
diets228. Conversely, our findings are supported by multiple prospective large-scale cohort
studies, which have consistently found that maternal obesity and gestational weight gain, in the
absence of other complications, are associated with increased placental size

229–233

. While not a

identical representation of the present model, these human studies support the notion that
maternal overnutrition may be a driving factor of abnormal placental growth.
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Clinically placental size has been largely correlated with the size of the fetus, reflecting
increased nutrient transport capacity; yet, the present findings showed only minor increases in
the body weight and volumes of WD fetuses230,231. This led to questioning the placental
efficiency of the described WD model. Fetal to placental weight ratios were compared between
diet groups as a proxy of placental efficiency, which was found to be reduced in the WD
placentae. Thus, it is evident that the additional placental weight and volume associated with WD
exposure did not increase the functional capacity of placentae in the current model. Similar
reductions in placental efficiency have been noted in human pregnancies complicated by obesity
and maternal high-fat diets229,232–234. The mechanisms underlying these changes are unclear,
although it was suggested that maternal overnutrition may lead to structural abnormalities and/or
functional disruptions in the placenta that limit fetal nutrient supply231,232. Alternatively, it has
been postulated that increases in placental weight in response to overnutrition may be attributed
to tissue remodelling in an attempt to adapt to tissue damage and preserve placental function231.
4.2.2 Placental Pathology
In view of the foundational role of the placenta in fetal development, understanding the
etiology of the noted reductions in placental efficiency was essential to elucidating the impact of
maternal WD consumption. To investigate the quality of the placental tissues, the placentae were
scored for necrosis and fibrin thrombi. WD placentae had greater total pathology scores,
suggesting greater levels of widespread and severe placental pathology. Necrosis specifically
was frequently observed in these placentae and was correlated with the occurrence of organizing
fibrin and/or fibrin thrombi, although there were no dramatic changes in fibrin alone.
Furthermore, these pathology scores were positively correlated with placental size, suggesting
that the larger placentae showed greater distribution and severity of necrosis and fibrin
deposition. This lends support to the theory that increased placental weights may be the
consequence of tissue remodelling or edema following placental infarcts induced by maternal
overnutrition.
These features may also be an indication of disrupted integrity of the placental labyrinth,
which in the guinea pig placenta houses fetal capillaries and is the structure chiefly responsible
for nutrient and gas exchange235. Defects in the integrity of the labyrinth can lead to edema and
thrombosis, leading to infarcts which may disrupt blood flow235. Inadequate perfusion of the
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labyrinth can lead to tissue fibrosis and necrosis, which ultimately limits surface area for nutrient
and gas exchange235. Typically these findings—particularly fibrin deposition and thrombosis—
are associated with impaired fetal growth, which was not an outcome observed in the current
study population235–237. Previous unpublished work in our lab conducted on 40-day placentae of
the same WD model found reduced fetal capillary size, which might further implicate altered
labyrinth structure in the noted reduction in placental efficiency. It is yet to be discovered if these
outcomes are consistent in the current 65-day model used in the present study.
While the exact findings differed between studies, maternal overnutrition has been
previously associated with various pathological findings and altered villous integrity in the
placentae of humans, non-human primates, and guinea pigs; but, the etiology of these changes is
poorly understood117,209,230. Oxidative stress and/or inflammation are possible suspects of
mediating the structural and functional changes observed in the placentae, given that they have
both been found to increase in the placentae of over-nourished mothers117,238,239. The present
findings cannot confirm nor deny whether the current observed placental changes are attributable
to placental inflammation or oxidative stress; however, this is a question that warrants further
research to further characterize this maternal WD model.
Nonetheless, the present findings reflect severe changes in placental structure occurring
in association with lifelong maternal WD consumption independent of obesity. These changes
likely contribute to functional disruptions in the placenta and may be involved in altering the
trajectory of fetal development.

4.3 BDNF expression
4.3.1 BDNF expression in the placenta
One of the placenta’s major functions is the production of hormones and growth factors,
one of which being BDNF, a growth factor with trophic effects in both the placenta and fetal
brain46,128. As such, relative placental BDNF protein expression was investigated by western blot
analysis, which highlighted lower protein levels in the placentae of fetuses exposed to maternal
WD consumption. Furthermore, correlation analysis revealed a negative correlation between
placental BDNF expression and pathology scores, pointing to a relation between BDNF
expression and the health of the placental tissue.
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It is difficult to understand the nature of this relationship since it is unclear which was the
precipitating factor. For one, the cytotrophoblasts and syncytiotrophoblasts, are thought to
constitutively express BDNF128,240. Thus, apoptosis or cellular damage such as necrosis would
likely reduce the placenta’s functional capacity to produce hormones and neurotrophic factors
such as BDNF. On the other hand, placental cells like the cytotrophoblasts and EVTs, which
express the TrkB receptor, are responsive to its local expression. BDNF supports the growth and
development of the placenta by promoting cytotrophoblast proliferation, differentiation, and
survival, supporting the formation of the placental villi and their exchange surface area122.
Furthermore, the role of BDNF in angiogenesis has been established in multiple tissues; it has
been proposed that it may likewise contribute to the development and maintenance of the
placental vasculature, which is further supported by the finding that the TrkB receptor is
expressed on cells of the fetal endothelium within the placental villi

120,136,138,241–243

. This theory

is strengthened by the negative correlation previously reported between placental BDNF and
blood pressure (systolic and diastolic), as well as its noted reduction in preeclamptic human
placentae138. These proposed mechanisms reflect pathways through which placental pathology
may both contribute to, and be induced by, reduced BDNF expression.
The argument that the reductions in BDNF preceded placental infarct in the current
model is strengthened by BDNF’s reported sensitivity to maternal nutritional challenges,
showing altered expression patterns following both maternal over- and under-nutrition in both
humans and animal models139,241. With regards to maternal overnutrition specifically, previous
clinical studies have reported reduced placental expression of BNDF, its receptors, and
downstream effectors in the context of maternal obesity139. These changes were attributed to
alterations in BDNF gene methylation, which is consistent with outcomes reported following
exposure to perinatal maternal stress48,133,139. The present findings are novel in that they are the
first to extend the association of maternal overnutrition and reduced placental BDNF expression
to include maternal WD consumption in the absence of obesity.
Given BDNF’s apparent sensitivity to nutritional imbalances, it is speculated that
maternal WD consumption alters BDNF expression, diminishing its trophic signalling in the
placenta. This in turn, may lead to abnormal placental development and subsequent tissue
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damage, which further impedes BDNF production in a positive feedback loop that perpetuates
placental damage.
4.3.2 BDNF expression in the fetal brain
In the fetal brain, BDNF derived from both the placenta and endogenous fetal production
is involved in nearly all developmental functions; thus, alterations in its expression, particularly
in regions where it is abundantly expressed, may lead to severe cognitive deficits46,48. To
investigate whether the observed changes in placental BDNF expression in response to maternal
overnutrition extended to the fetal brain, immunostaining was used to measure BDNF protein
levels in three regions where its expression is established46,48. The localization of BDNF protein
was confirmed in the extracellular environment of hippocampal regions DG and CA3, as well as
the thalamus. Across all regions, both the area and integrated optical density of BDNF
immunoreactivity were reduced in the WD fetuses, representing lower BDNF protein expression.
The validity of these findings is supported by others who have reported similar reductions
in BDNF mRNA and protein levels postnatally in the hippocampus of murine offspring exposed
to maternal high-fat or high fructose diets, even when switched to a control diet
postnatally97,112,244. Interestingly these outcomes, along with the present fetal findings, mirror
those which were previously observed in adult rodent models who adhered to the western dietary
pattern183. As previously noted, BDNF has been proposed as a nutrient sensor, although this
relationship has largely been discussed with regards to its expression in the hypothalamus155.
Collectively these findings suggest that BDNF expression in the hippocampus and thalamus are
similarly regulated by nutritional status, although the underlying mechanisms and implications
are still to be defined. Epigenetic modifications of the BDNF gene are a promising theory given
that altered methylation patterns of the BDNF promoter have been reported in the brains of
offspring exposed to maternal high-fructose diets, as well as the brains of mature animals
exposed to chronic high-fat diets, either through increased methylation or decreased
demethylation181,244. Moreover, there is evidence that suggests epigenetic modifications of
BDNF are triggered by alterations in energy status, specifically the NAD+/NADH ratio and
mTOR pathway181,245. As outlined by these studies, increased fetal nutrient availability resulting
from maternal WD consumption may promote epigenetic modifications—likely alterations to
DNA methylation patterns—that suppress BDNF expression in the fetal brain.
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On the other hand, these reductions may be the product of the specific macronutrient
composition unique to the WD. In the present study, the experimental WD contained
approximately 32% SFA, 12% MUFAs and 2% PUFAs, contrasting the composition of the CD
which contained 3% SFA, 4% MUFAs, and 11% PUFAs. One study in mice reported reductions
in fetal hippocampal BDNF and its TrkB receptor in response to maternal diets low in omega-3
PUFAs independent of the diet’s total fat content246. A similar study conducted in mice reported
upregulation of BDNF and its downstream effectors in response to high maternal omega-3 PUFA
consumption185. Moreover, maternal diets deficient in omega-3 PUFAs confer increased DNA
methylation of the BDNF gene in the brains of mouse offspring postnatally, thus reducing its
long-term expression247. Taken together it is speculated that the fatty acid ratio of the WD is in
part responsible for the detrimental effects presently observed on BDNF expression in the fetal
brain.
It would be remiss not to mention the potential influence of oxidative stress and
inflammation. Previously it was shown in an adult murine model that the WD reduced the
expression of BDNF and its downstream effectors; however, these effects were mitigated with
aerobic exercise47,248. In addition to reversing the diet’s effect on BDNF expression, levels of
oxidative stress were also reduced. While the relationship between maternal oxidative stress and
its prevalence within the fetal brain is not clear, there is evidence that maternal diet may be
increasing ROS production in the fetal brain. For example, one study noted that lipid
peroxidation was accompanied by decreased BDNF expression in the hippocampus of mouse
offspring born to high-fat-fed dams112. Just as overnutrition and metabolic dysfunction have been
found to increase oxidative stress, so too are they associated with chronic low-grade
inflammation, termed “metainflammation’93. This may be relevant to the present findings given
that experimentally induced inflammation is capable of suppressing BDNF expression and
signalling166,167. Perhaps more convincing is that neuroinflammation has been found in
association with reductions in BDNF expression following chronic exposure of mice to a highfat diet249. It has been postulated that maternal inflammation in the context of metabolic
dysfunction or dietary patterns may confer similar inflammation in the fetus, possibly through
placental production of pro-inflammatory cytokines93,117. The presence of oxidative stress and
inflammation remains a possible suspect of mediating changes in fetal BDNF expression
following maternal WD consumption and metabolic dysfunction; however, these claims are
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made with the caveat that currently the oxidative and inflammatory status of the present model
remains to be discovered.
Finally, reductions in BDNF expression in the fetal brain may be directly attributed, at
least in part, to its reduced expression in the placenta. Maternal-derived BDNF has been found to
cross the uteroplacental barrier and has been noted in the fetal brains of mice at multiple
timepoints during pregnancy, including at term98. Moreover, the same study found levels of
BDNF in the placenta to be positively correlated with that of the fetal cord blood, supporting the
notion that placental-derived BDNF is directly supporting fetal development98. A reduction in
placental production or delivery of BDNF to the fetus may then be reflected in reduced protein
levels in the brain, as was currently reported. This is unlikely to be the sole cause of BDNF
reduction given that the fetuses’ reliance on maternally-derived BDNF diminishes as pregnancy
progresses and the current model reflects a fetus near term98. It is more likely that reduced supply
early in pregnancy communicates deficits to early fetal brain development that alter its intrinsic
expression of BDNF later in adulthood. For example, these differences may reflect decreased
cell density. As a regulator of cell proliferation and survival, higher levels of placental-derived
BDNF during early periods of neurogenesis would promote larger cell populations46. Neurons
and microglia are both responsible for the production and secretion of BDNF, thus a reduction in
cell density may be both cause and effect of reduced BDNF expression.
At present, there is not enough information to conclusively determine the cause of noted
BDNF reduction, although it is likely the culmination of one or more of the factors discussed
above. Nonetheless, this remains an important point of discussion given its vital role in
neurodevelopment both in utero and beyond.

4.4 Impact of Maternal WD on fetal neurodevelopment
4.4.1 Cell proliferation
BDNF is involved in nearly all developmental processes throughout gestation, some of
which continue into late gestation and later life. One such process is hippocampal neurogenesis,
which along with synaptic pruning and synaptogenesis, is responsible for brain plasticity152. To
understand the implications of lifelong maternal WD consumption on fetal hippocampal
neurogenesis, brain sections were stained for Ki67, a marker of cell proliferation. Between fetal
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diet groups, no changes were noted in the number of Ki67 immunoreactive cells in any region of
the hippocampus, suggesting there were no changes in cell proliferation. These results were
surprising. Given that BDNF has been shown to promote cell proliferation and neurogenesis in
the brain, it was expected that cell proliferation would decrease in parallel with BDNF
expression in the hippocampus of WD Fetuses148,250. These suspicions are further grounded in
evidence from previous studies that found diets rich in saturated fats and refined sugars
consumed postnatally or experienced through maternal consumption during gestation, reduced
hippocampal neurogenesis184,244,251
BDNF exerts its effects on proliferation through its TrkB receptor46. As such,
hippocampal cell proliferation has shown positive correlations to the receptor’s expression252. In
one previous study conducted in guinea pigs, fetal hippocampal expression of BDNF and its
receptor showed an inverse relationship—albeit under different adverse intrauterine conditions
than that which was explored in the present study253. They proposed the observed upregulation of
TrkB receptor expression was a compensatory mechanism responding to reduced BDNF
expression, which has been similarly documented under other post-natal conditions254. While
reductions in fetal hippocampal BDNF expression were noted in the current study following
maternal WD consumption, TrkB expression was not reported and remains unknown.
Differential expression or localization of the TrkB receptor may modify the impact of reduced
BDNF expression, although these changes would not be without their own consequences.
The present results may otherwise be a product of the time point studied. Previous studies
that have reported a relationship between reduced BDNF and hippocampal neurogenesis have
been primarily conducted on post-natal animals184,244,251. This makes it easy to speculate that
detriments to hippocampal neurogenesis may not manifest until later in postnatal life. However,
an important caveat to interpreting these studies is recognizing their use of a rat or mouse model,
which both exhibit delayed neuronal maturation relative to guinea pigs and humans91,255. Unlike
most rodents, guinea pigs undergo expansive neurodevelopment in utero; thus, when comparing
developmental timelines, the aforementioned rodent studies may be comparable to the time point
presently studied91,255,256. In agreement with this statement, approximately 80% of the granule
cells in the hippocampus are produced prenatally in the guinea pig much like humans255. As
such, one might expect hippocampal neurogenesis to steadily decline throughout gestation and
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postnatal development; however, this is not the case. Hippocampal neurogenesis in the guinea
pig shows a postnatal peak on day 3 after birth, showing a 1.5-fold increase between post-natal
days 1 and 3255. It has been proposed that cell genesis in the guinea pig brain is temporarily
inhibited near term and then resumed postnatally, as is the case for the rat255. The present study
observed the fetal brain at gestational day 65, which is 3 days prior to expected delivery and 1
week prior to when hippocampal neurogenesis is expected to peak. Greater differences in cell
proliferation may have been noted at either an earlier period of prenatal development or during
postnatal life.
In utero, BDNF is sourced from the mother, placenta, or endogenous fetal production142.
Without understanding which of these factors is primarily driving the observed reduction in
BDNF noted in the fetal brain, it is difficult to draw conclusions. Even if maternal and/or
placental sources were somewhat reduced, their supply of BDNF may help to mitigate the effects
of reduced endogenous production in the fetal brain (assuming endogenous production is
reduced). If this were the case, the effects of reduced BDNF expression on hippocampal
neurogenesis may not manifest until the alternative sources are eliminated, as is the case after
birth142.
From the findings reported here, hippocampal neurogenesis appears unaffected by
lifelong maternal WD consumption in near-term fetuses; however, this does not absolve the fetal
brain from developmental deficits resulting from the WD-induced declines in BDNF expression.
4.4.2 Cell density
The role of BDNF in promoting neurogenesis begins early in gestation with the rapid
expansion of the fetal brain. Given that hippocampal cell proliferation appeared unchanged near
term, cells were counted to determine whether differences existed in cell density between diet
groups. Hematoxylin-stained cells were counted in the hippocampus and thalamus, which was
included in this analysis as it showed similar reductions to the hippocampus in BDNF
expression.
WD fetuses showed reduced cell density across all brain regions, which was expected
given that maternal overnutrition has been shown to negatively impact the size and cell density
of the brain, particularly the hippocampus. For example, it was observed that children (7-11
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years) born to obese mothers had reduced hippocampal volumes as determined by MRI257.
Similarly, rodent models have demonstrated that maternal diets high in saturated fat are
associated with reduced neurogenesis, which may drive reduced cell density114,184,250. On the
other side of the macronutrient spectrum, the work of Erbas et al demonstrated that a diet high in
fructose was associated with increased hepatic lipid accumulation in a maternal rat population,
just as it was noted in the guinea pig in the present study following WD consumption258.
Moreover, following in utero exposure to this maternal metabolic environment, offspring
showed reduced hippocampal cell density in tandem with increased expression of proinflammatory cytokines258. Collectively these findings support the notion that maternal WD
consumption is the catalyst of the observed reduction in cell density, although the mechanisms
behind this change are less clear.
Healthy neurodevelopment involves both cell proliferation and apoptosis, a delicate
dichotomy that is maintained by the balance of pro-survival and pro-apoptotic signals81. As
previously discussed, WD consumption and related metabolic dysfunction, including the
NAFLD phenotype observed in the present maternal population, are associated with increased
levels of inflammation and oxidative stress in the maternal and fetal environments93,258,259. In
addition to their detrimental impact on BDNF signalling, inflammation and oxidative stress
appear to impede neurogenesis and promote cellular damage, potentially altering the balance
between cell survival and death260. As it relates to BDNF, the neurotrophic factor’s role in
neurogenesis has been well established; however, some have suggested its trophic effects in the
brain are attributable to increased cell survival of the newly generated neurons, rather than
increased cell proliferation147,250. BDNF may then reduce rates of apoptosis in the brain by acting
as a pro-survival signal. Given that cell proliferation appeared unchanged in the hippocampus of
the currently studied WD fetuses, the current WD model may be perpetuating cellular damage
through the induction of inflammation and/or oxidative stress, while simultaneously reducing
pro-survival signalling through the suppression of BDNF expression. Together these
mechanisms would enhance the susceptibility of the brain cells to cell death leading to reduced
cell density.
In light of the fact that the presence of inflammation and oxidative stress in the present
model can only be speculated, a simpler explanation may be that the noted decrease in cell
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density is a product of earlier disruption in neurodevelopment resulting from altered placental
function. As previously discussed, the placenta is an important source of BDNF early in
gestation prior to the expansion of the fetal brain98. Considering that the present model features
lifelong (including pregnancy) maternal WD consumption, the noted reductions in placental
BDNF expression may be consistent throughout gestation. It would then be plausible that the
initial formation of brain structures like the hippocampus and thalamus could be disrupted, either
by reduced cell proliferation or decreased cell survival, resulting from decreased BDNF delivery
from the placenta. Given that changes in cell density were noted in the thalamus, a region where
continued neurogenesis is not expected in a term fetus, it is likely that the reported changes in
cell density arose at an earlier period of neurodevelopment during global cell proliferation. To
this end, evaluating cellular proliferation at an earlier time point in pregnancy may better
elucidate whether the current reductions in cell density are a product of early changes in
proliferation or rather increased levels of cell death at a later timepoint in pregnancy.
These findings reflect that maternal WD consumption independent of obesity can confer
significant changes to cell density in vital brain structures such as the hippocampus and
thalamus. As the center regulating learning, memory, and mood, these changes may confer
severe detriment to the cognitive function of offspring and potentially predispose them to the
development of future neurological disorders.
4.4.3 Microglia cell density and activation state
As the resident immune cells of the brain, microglia are often discussed in relation to
neuroinflammation and disease pathology. While aberrant microglial activation does perpetuate
neuroinflammation and consequently neurological pathology, microglia are also beneficial in
supporting cell proliferation, survival, and differentiation49. The exact effects of microglia are
dependent on the extent of their activation as well as their specific phenotype or activation state,
which is heavily related to their morphology and cell-surface receptor expression49.
Consequently, morphological characteristics of microglial activation are often used as an
indicator of neuroinflammation, specifically by quantifying their transition from a highly
ramified state to an ameoboid-like morphology that is characteristic of activated microglia160,208.
In the present study, both microglia cell density and morphology were evaluated by
immunostaining for Iba1, a microglia cell marker. Microglial morphology was evaluated based
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on cell body size and roundness, and the cell body size to process length ratio to reflect changes
in activation state. Across all the brain regions studied, there was no difference noted in
microglial cell density, nor any of the morphological parameters, suggesting that microglial
populations in the fetal brain regions studied were unaffected by lifelong maternal WD
consumption.
An important caveat to the present findings is that there are no standardized
classifications for the various microglial phenotypes. Beyond the traditional “activated” vs
“resting” state classification that is often used to describe microglia populations, alternative
morphological phenotypes are not fully understood49,208. The activated state, for example,
encompasses multiple phenotypes with varying functions49. This is an important distinction
because certain populations of activated microglia have been shown to mediate antiinflammatory responses that are vital to brain repair following acute inflammation or ischemia,
including the secretion of BDNF49,158,163. Nonetheless, it still follows that neuroinflammation
would likely result in an increase to both the total and the activated microglia cell populations,
with the specific activation states of the population being dependent on the duration and nature
of the precipitating insult158. Given that no changes were observed in microglia cell density or
morphology, this suggests that neuroinflammation may not be present in fetal brains challenged
with maternal gestational WD consumption.
These findings were surprising given the associations of maternal WD consumption and
subsequent metabolic inflammation with increased offspring expression of inflammatory
cytokines. In the offspring of high-fat-fed macaque mothers, there were noted increases in both
the population and activation of microglia, as well as in the expression of interleukin 1 beta (IL1β) inflammatory cytokines and the IL-1 receptor119. In a similar rat model of maternal high-fat
consumption, these findings were corroborated with offspring showing enhanced microglial
activation in tandem with increased expression of IL-1β and toll-like receptor 4 (TLR4),
signalling through the latter of which enhances inflammatory cytokine production113.
Conversely, in rat offspring born from mothers with fructose-induced hepatic lipid accumulation,
the expression of tumour necrosis factor-alpha (TNF-α) was increased258. These studies implicate
maternal consumption of diets like the WD in enhancing the inflammatory state of the fetal
brain. Variability in animal models, diet composition, and age of subject offspring between
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studies may likely account for inconsistencies in the current results and those previously
reported. Additionally, it should be noted that in the absence of additional markers of
neuroinflammation, such as the inflammatory cytokines and receptors discussed above,
conclusions and comparisons regarding the inflammatory state of the fetal brain are made
difficult.
The lack of change in microglial cell number and activation state helps to contextualize
some of the present findings. As mentioned, BDNF can be secreted by activated microglia,
typically following acute inflammation, to facilitate tissue repair158. The reported findings
eliminate microglia from being considered as a major source of the BDNF observed in the brains
of CD fetuses. Secondly, these findings strengthen the argument that the observed reduction in
cell density is attributable to a decrease in neuronal cell populations, although other glial cell
types (astrocytes and oligodendrocytes) cannot be completely discounted.
Taken together, while no changes in the microglial population were observed, this
analysis provided valuable insights that helped to contextualize other findings contained within
the present study. The analysis also highlighted the importance of utilizing additional markers to
better understand microglia activation and to characterize the inflammatory state of the brain.

4.5 Limitations
While care was taken to ensure the quality and utility of the present research, this study is
not without limitations. First, the present study was focused on the outcomes of near-term
fetuses. As such these findings represent only a snapshot of development that may not reflect
additional changes occurring earlier in gestation or immediately post-birth during other critical
windows of brain development. In the present study, in utero fetal demise occurring near the end
of pregnancy was noted amongst the WD group and due to the integrity (or complete
reabsorption) of tissues, these fetuses were excluded from all analyses. As a result, valuable fetal
specimens were lost that may have provided greater insight into more severe consequences
related to maternal diet. Moreover, it is difficult to form conclusions about the long-term
cognitive outcomes of these fetuses, given that brain development is a fluid process that
continues postnatally and is subject to further modifications by environmental factors.
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Moreover, interpretation of this study’s results is limited by the diet itself. The
experimental WD was designed to mimic a human WD as described by Cordain et al, which is
characterized by a particular proportion of fatty acids and simple sugars199. Consequently, the
current study cannot distinguish between the effects of added simple sugars versus added
saturated fats. Tangentially, food was provided to the sows in solid pellet form, which does not
account for the prevalent intake of fructose/sucrose sweetened beverages involved in a typical
WD. This is a limitation because there is epidemiological evidence to suggest that simple sugars
may have enhanced metabolic detriment when consumed in liquid form261,262. Thus, by nature of
the current experimental diet design, detriments of true WD consumption may be minimized.
In addition, this study was limited by sample size, which prevented fetal sex from being
included in the analysis. There is a plethora of evidence to suggest that the outcomes from
intrauterine adversity differ between sexes257,263,264. As it pertains to the present study, sex
differences have been specifically noted in BDNF expression139. Thus, while there were notable
differences in features of fetal and placental development, the current study cannot statistically
speak to sex differences in vulnerability to maternal overnutrition. It should also be noted that
maternal populations were also particularly small, which drastically reduced statistical power of
the maternal analysis; however, analyses were included as they were consistent with phenotypes
previously reported by our lab in larger sample populations195,196,265.
Finally, the interpretation of this study is limited by the prevalent use of
immunohistochemistry for fetal brain characterizations. Although useful for determining the
localization of protein expression and for visualizing changes in brain morphology, this
technique identifies changes in only a single cross-section of the tissue. Consequently, there may
be changes in adjacent brain regions that are not captured. Analyses of cell proliferation and cell
density were further limited because they were conducted without the use of additional neuronal
markers. Neither Ki67 nor hematoxylin is specific to neurons, thus any changes in their
expression cannot be wholly attributed to changes in the neuronal cell population. This lack of
specificity muddies the findings making it difficult to form conclusions around the impact of
maternal WD on fetal neurogenesis and it highlights the importance of using additional markers
that identify neurons like NeuN.
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4.6 Future works
The present study revealed several fascinating avenues of future research, some of which
expand on the current findings and others that help to fill in the remaining gaps in knowledge.
First, this study highlighted reduced BDNF expression in the placenta and fetal brain. While it
can be assumed that this would convey detriments to brain development, BDNF is only the
catalyst of what is a complex signalling pathway. To fully understand the implication of this
reduction, further investigation is required. Of particular interest would be the expression of the
TrkB receptor in the placenta and fetal brain, expression of which has previously been shown to
change following perinatal adversity130,139,246,266. Changes in receptor expression may ultimately
be mitigating or exacerbating the changes noted in BDNF expression, thus such an analysis
would complement the current findings and would offer insight into the extent to which the
noted reduction in BDNF might affect either tissue.
Secondly, as has been alluded to numerous times, a major gap in the presented research is
the missing characterization of inflammation in the placental and fetal brain of the current model.
The WD has been described as pro-inflammatory and maternal overnutrition has likewise been
associated with chronic low-grade inflammation1,93. Moreover, in such circumstances, the
placenta itself may produce its own inflammatory cytokines117. Microglial activation was
explored in the fetal brain as a proxy for neuroinflammation, but in the absence of additional
inflammatory markers, it is not clear whether maternal WD consumption is affecting levels of
inflammation in the fetal brain. Given the antagonistic effects of chronic inflammation on BDNF
expression, identifying the inflammatory state of both tissues would be pertinent to clarifying the
underlying etiology of the reported placental and neurological changes. To this end, future
studies should aim to characterize the cytokine profile of both the placenta and fetal brain in the
current WD model.
While characterizing the above features would be of use in the current population,
expanding the present research to include a larger sample size would allow sex to be adequately
considered in future analyses, improving the relevance and applicability of the present research.
Finally, this study highlighted changes in the fetal brain at term. The noted reduction of
BDNF expression in the hippocampus is of particular interest because as a region involved in
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memory, learning, and mood regulation, such changes are expected to bring about behavioural
and cognitive deficits. Neurobehavioural studies in a future cohort of neonates born to WD-fed
sows would be of value to better understand how these changes in BDNF expression affect
cognition and behaviour. Beyond cognitive function, evaluating the food intake of these neonates
would also be relevant. Hyperphagic obesity is a well-established phenotype of the Val66Met
mutation and inhibition of BDNF-TrkB signalling has led to similar outcomes48,53. The observed
decreases in BDNF expression may not only confer cognitive deficits but also dysregulate satiety
signalling further perpetuating metabolic dysfunction.

4.7 Conclusion
The present study was guided by the governing hypothesis that lifelong maternal WD
consumption, even in the absence of obesity, would alter fetoplacental development in a guinea
pig model, specifically as it pertained to placental and fetal neurodevelopment. The findings
reported here stand to support this hypothesis.
The first objective was to characterize the phenotypes of maternal and fetal animals to
elucidate potential changes that may be associated with chronic exposure to a western dietary
pattern. Within the mothers themselves, lifelong WD consumption was associated with hepatic
lipid accumulation, independent of additional extrahepatic adiposity. This phenotype was
conserved in both mother and fetus, although it is speculated these outcomes may be driven by
different mechanisms. Maternal NAFLD is postulated to be largely a result of the additional
fructose found in the WD, as an added sugar that has been known to reduce hepatic oxidation
and increase de novo lipogenesis in the liver, while promoting the oxidation of peripheral
adipose tissues219–221. Regarding the fetal population, these findings are more likely the response
of primitive adaptive mechanisms that promote lipid storage in utero in response to a mismatch
between maternal supply and fetal demand225. Given that the guinea pig, much like humans, do
not lay down adipose tissue until late gestation, mismatches present earlier in gestation, as is the
case with lifelong maternal WD consumption, may instead promote triglyceride accumulations in
fetal organs such as the liver, setting the stage for young adulthood NAFLD80,196,225
Attention was then shifted to the second component of the fetoplacental unit, to the vital
organ regulating fetal development. The second objective was to identify changes in placental
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development arising from maternal adherence to WD consumption. The diet was associated with
larger, less-efficient placentae and the detriments in placental efficiency were likely attributable
to some form of placental infarct, as there was a higher prevalence of necrosis and fibrin thrombi
in these functionally deficient placentae. The exact cause of these findings remains a fascinating
avenue for future study.
Among the many functions of the placenta is its production of hormones such as BDNF,
a trophic factor that supports the development of both the placenta and the fetal brain and is
largely regulated by changes in nutritional status46,128,137. The third objective was to characterize
its expression in both the placenta and the fetal brain to determine whether expression in either
tissue was being influenced by maternal diet. To this end, it was demonstrated that BDNF
expression was notably reduced in the placentae and in multiple regions of the fetal brain. Given
BDNF’s established regulation by energy status, it is speculated that maternal overnutrition may
have reduced its expression in the early developing placenta155,267,268. Such a reduction would
attenuate trophic support of placental development, which may cause placental infarcts that
further limit the functional capacity of placental cells to produce BDNF later in pregnancy.
Within the brain, the cause of BDNF reduction is less clear and likely results from the
combination of reduced placental delivery and suppressed fetal endogenous production.
Regardless these findings are grounds for concern, particularly if maintained after birth given the
multiple roles of BDNF in the developing brain46.
The noted reductions in BDNF expression highlighted the potential impact of maternal
WD consumption on fetal brain development. This led to the fourth and final objective, to
broadly investigate potential disruptions in the balance of neurogenesis and neuroinflammation
during neurodevelopment. No changes in cell proliferation were observed in the hippocampus,
suggesting that in a near-term fetus, hippocampal neurogenesis remains unchanged despite the
concurrent reduction in BDNF. Conversely, cell density in the hippocampus and thalamus were
lower under the WD condition. Together these findings may indicate disruption of early
neurogenesis or increased rates of apoptosis following the suppression of BDNF expression.
Originally it was speculated that the changes in the fetal brain may be explained by the presence
of inflammation, as is commonly found in association with maternal metainflammation93. The
present study does not support this claim given that microglia populations remained unchanged
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both in cell density and activation levels; however, further investigations of pro-inflammatory
cytokine expression in the fetal brain would be useful to confirm these results.
Collectively, here it was shown that lifelong maternal WD consumption in the context of
a metabolically unhealthy but lean maternal phenotype, may confer metabolic and cognitive
detriments to the fetus that are in part related to alterations in the placental function. The present
study has only scratched the surface of the neurodevelopmental changes that may be born out of
a reduction in fetoplacental BDNF expression. While the impact of these changes postnatally
remains to be determined, they are likely to confer long-term detriments to memory, learning,
and behaviour. These findings underscore the importance of viewing maternal metabolic health
holistically, which means considering lifestyle factors such as dietary patterns, independent of
body composition, as key predictors of metabolic health. Habitual WD consumption before and
during pregnancy, even with a lean phenotype, is a risk factor of future metabolic and cognitive
disruption in offspring through in utero fetal reprogramming.

Figure 4.7.1-1. Lifelong maternal western diet consumption, even in the absence of obesity, can
have detrimental effects on both placental and fetal brain development. These changes are likely
attributed in part to alterations in BDNF protein expression as a consequence of maternal
overnutrition.
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APPENDICES
Appendix A:
Animal Use Protocol:
AUP Number: 2019-116
AUP Title: Hyperpolarized 13C MRI of Placental Metabolic Abnormalities Resulting from the
Western Diet
Yearly Renewal Date: 02/01/2022
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2019-116 has been approved by
the Animal Care Committee (ACC), and will be approved through to the above review
date.
Please at this time review your AUP with your research team to ensure full understanding by
everyone listed within this AUP.
As per your declaration within this approved AUP, you are obligated to ensure that:
1) Animals used in this research project will be cared for in alignment with:
a) Western's Senate MAPPs 7.12, 7.10, and 7.15
http://www.uwo.ca/univsec/policies_procedures/research.html
b) University Council on Animal Care Policies and related Animal Care Committee
procedures
http://uwo.ca/research/services/animalethics/animal_care_and_use_policies.html
2) As per UCAC's Animal Use Protocols Policy,
a) this AUP accurately represents intended animal use;
b) external approvals associated with this AUP, including permits and
scientific/departmental peer approvals, are complete and accurate;
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c) any divergence from this AUP will not be undertaken until the related Protocol
Modification is approved by the ACC; and
d) AUP form submissions - Annual Protocol Renewals and Full AUP Renewals - will be
submitted and attended to within timeframes outlined by the ACC.
http://uwo.ca/research/services/animalethics/animal_use_protocols.html
3) As per MAPP 7.10 all individuals listed within this AUP as having any hands-on animal
contact will
a) be made familiar with and have direct access to this AUP;
b) complete all required CCAC mandatory training (training@uwo.ca); and
c) be overseen by me to ensure appropriate care and use of animals.
4) As per MAPP 7.15,
a) Practice will align with approved AUP elements;
b) Unrestricted access to all animal areas will be given to ACVS Veterinarians and ACC
Leaders;
c) UCAC policies and related ACC procedures will be followed, including but not limited
to:
i.

Research Animal Procurement

ii.

Animal Care and Use Records

iii.

Sick Animal Response

iv.

Continuing Care Visits

5) As per institutional OH&S policies, all individuals listed within this AUP who will be using
or potentially exposed to hazardous materials will have completed in advance the appropriate
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institutional OH&S training, facility-level training, and reviewed related (M)SDS Sheets,
http://www.uwo.ca/hr/learning/required/index.html

Submitted by: Copeman, Laura
on behalf of the Animal Care Committee
University Council on Animal Care
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Appendix B:
R Code for Fetal Statistical Analyses
install.packages("lme4")
install.packages("learnr")
install.packages("emmeans")
library(lme4)
library(lmerTest)
library(emmeans)
MRIdata <- read.csv("C:/Users/cciho/OneDrive/Desktop/MRIdata.csv")
MRIdata
fetal.v_model <- lmer(fetal.v~diet + (1|maternal_id), MRIdata)
placenta.v_model <- lmer(placenta.v~diet + (1|maternal_id), MRIdata)
TAT.bodyv_model <- lmer(TAT.bodyv~diet + (1|maternal_id), MRIdata)
brain.bodyv_model <- lmer(brain.bodyv~diet + (1|maternal_id), MRIdata)
liver.bodyv_model <- lmer(liver.bodyv~diet + (1|maternal_id), MRIdata)
pdff_model <- lmer(pdff~diet + (1|maternal_id), MRIdata)
emmeans(object=fetal.v_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=placenta.v_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=TAT.bodyv_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=brain.bodyv_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=liver.bodyv_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=pdff_model, pairwise ~ diet, adjust= "t-test")
animaldata <- read.csv("C:/Users/cciho/OneDrive/Desktop/animaldata.csv")
animaldata
fetal.w_model <- lmer(fetal.w~diet + (1|maternal_id), animaldata)
placenta.w_model <- lmer(placenta.w~diet + (1|maternal_id), animaldata)
fetal.placenta_model <- lmer(fetal.placenta~diet + (1|maternal_id), animaldata)
brain.bodyw_model <- lmer(brain.bodyw~diet + (1|maternal_id), animaldata)
liver.bodyw_model <- lmer(liver.bodyw~diet + (1|maternal_id), animaldata)
emmeans(object=fetal.w_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=placenta.w_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=fetal.placenta_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=brain.bodyw_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=liver.bodyw_model, pairwise ~ diet, adjust= "t-test")
placentaldata <- read.csv("C:/Users/cciho/OneDrive/Desktop/placentaldata.csv")
placentaldata
pathology_model <- lmer(pathology~diet + (1|maternal_id), placentaldata)
necrosis_model <- lmer(necrosis~diet + (1|maternal_id), animaldata)
fibrin_model <- lmer(fibrin~diet + (1|maternal_id), animaldata)
bdnf_model <- lmer(bdnf~diet + (1|maternal_id), animaldata)
emmeans(object=pathology_model, pairwise ~ diet, adjust= "t-test")
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emmeans(object=necrosis_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=fibrin_model, pairwise ~ diet, adjust= "t-test")
emmeans(object=bdnf_model, pairwise ~ diet, adjust= "t-test")
bdnfdata <- read.csv("C:/Users/cciho/OneDrive/Desktop/bdnfdata.csv")
bdnfdata
dgarea_model <- lmer(dgarea~diet + (1|maternal_id), placentaldata)
ca1area_model <- lmer(ca1area~diet + (1|maternal_id), placentaldata)
ca3area_model <- lmer(ca3area~diet + (1|maternal_id), placentaldata)
tarea_model <- lmer(tarea~diet + (1|maternal_id), placentaldata)
emmeans(object=dgarea_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca1area_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca3area_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=tarea_model, pairwise ~ diet, adjust= "t.test")
dgod_model <- lmer(dgod~diet + (1|maternal_id), placentaldata)
ca1od_model <- lmer(ca1od~diet + (1|maternal_id), placentaldata)
ca3od_model <- lmer(ca3od~diet + (1|maternal_id), placentaldata)
tod_model <- lmer(tod~diet + (1|maternal_id), placentaldata)
emmeans(object=dgod_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca1od_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca3od_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=tod_model, pairwise ~ diet, adjust= "t.test")
cellcountdata <- read.csv("C:/Users/cciho/OneDrive/Desktop/cellcountdata.csv")
cellcountdata
dg_model <- lmer(dg~diet + (1|maternal_id), cellcountdata)
ca1_model <- lmer(ca1~diet + (1|maternal_id), cellcountdata)
ca3_model <- lmer(ca3~diet + (1|maternal_id), cellcountdata)
t_model <- lmer(t~diet + (1|maternal_id), cellcountdata)
emmeans(object=dg_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca1_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca3_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=t_model, pairwise ~ diet, adjust= "t.test")
Ki67data <- read.csv("C:/Users/cciho/OneDrive/Desktop/Ki67data.csv")
Ki67data
dg_model <- lmer(dg~diet + (1|maternal_id), Ki67data)
ca1_model <- lmer(ca1~diet + (1|maternal_id), Ki67data)
ca3_model <- lmer(ca3~diet + (1|maternal_id), Ki67data)
emmeans(object=dg_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca1_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca3_model, pairwise ~ diet, adjust= "t.test")
Iba1data <- read.csv("C:/Users/cciho/OneDrive/Desktop/Iba1data.csv")
Iba1data
dg.cell.count_model <- lmer(dg.cell.count~diet + (1|maternal.id), Iba1data)
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ca1.cell.count_model <- lmer(ca1.cell.count~diet + (1|maternal.id), Iba1data)
ca3.cell.count_model <- lmer(ca3.cell.count~diet + (1|maternal.id), Iba1data)
t.cell.count_model <- lmer(t.cell.count~diet + (1|maternal.id), Iba1data)
cc.cell.count_model <- lmer(cc.cell.count~diet + (1|maternal.id), Iba1data)
emmeans(object=dg.cell.count_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca1.cell.count_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca3.cell.count_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=t.cell.count_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=cc.cell.count_model, pairwise ~ diet, adjust= "t.test")
dg.body.size_model <- lmer(dg.body.size~diet + (1|maternal.id), Iba1data)
ca1.body.size_model <- lmer(ca1.body.size~diet + (1|maternal.id), Iba1data)
ca3.body.size_model <- lmer(ca3.body.size~diet + (1|maternal.id), Iba1data)
t.body.size_model <- lmer(t.body.size~diet + (1|maternal.id), Iba1data)
cc.body.size_model <- lmer(cc.body.size~diet + (1|maternal.id), Iba1data)
emmeans(object=dg.body.size_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca1.body.size_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca3.body.size_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=t.body.size_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=cc.body.size_model, pairwise ~ diet, adjust= "t.test")
dg.body.circularity_model <- lmer(dg.body.circularity~diet + (1|maternal.id), Iba1data)
ca1.body.circularity_model <- lmer(ca1.body.circularity~diet + (1|maternal.id), Iba1data)
ca3.body.circularity_model <- lmer(ca3.body.circularity~diet + (1|maternal.id), Iba1data)
t.body.circularity_model <- lmer(t.body.circularity~diet + (1|maternal.id), Iba1data)
cc.body.circularity_model <- lmer(cc.body.circularity~diet + (1|maternal.id), Iba1data)
emmeans(object=dg.body.circularity_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca1.body.circularity_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca3.body.circularity_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=t.body.circularity_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=cc.body.circularity_model, pairwise ~ diet, adjust= "t.test")
dg.body.process_model <- lmer(dg.body.process~diet + (1|maternal.id), Iba1data)
ca1.body.process_model <- lmer(ca1.body.process~diet + (1|maternal.id), Iba1data)
ca3.body.process_model <- lmer(ca3.body.process~diet + (1|maternal.id), Iba1data)
t.body.process_model <- lmer(t.body.process~diet + (1|maternal.id), Iba1data)
cc.body.process_model <- lmer(cc.body.process~diet + (1|maternal.id), Iba1data)
emmeans(object=dg.body.process_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca1.body.process_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=ca3.body.process_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=t.body.process_model, pairwise ~ diet, adjust= "t.test")
emmeans(object=cc.body.process_model, pairwise ~ diet, adjust= "t.test")
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